搜索医生

Charles L. Loprinzi, M.D.

  1. Oncologist
预约门诊

出版物

  1. Premji SK, Ruddy KJ, Larson N, Loprinzi CL, Dulmage B, Lustberg M, Couch FJ, Olson JE, Cathcart-Rake E. Madarosis Among Breast Cancer Survivors. Clin Breast Cancer. 2024 Sep 6 Epub 2024 Sept 06
    View PubMed
  2. O'Sullivan CC, Larson NL, Vierkant RA, Smith ML, Chauhan C, Couch FJ, Olson JE, Loprinzi CL, Ruddy KJ. Advocate-BREAST: advocates and patients' advice to enhance breast cancer care delivery, patient experience and patient centered research by 2025. Arch Public Health. 2024 Aug 7; 82 (1):119 Epub 2024 Aug 07
    View PubMed
  3. D'Andre S, Novotny P, Walters C, Lewis-Peters S, Thomé S, Tofthagen CS, Giridhar KV, Loprinzi C. Topical Cannabidiol for Established Chemotherapy-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Trial. Cannabis Cannabinoid Res. 2024 Jul 17. [Epub ahead of print]
    View PubMed
  4. Stearns V, Jegede OA, Chang VT, Skaar TC, Berenberg JL, Nand R, Shafqat A, Jacobs NL, Luginbuhl W, Gilman P, Benson AB 3rd, Goodman JR, Buchschacher GL Jr, Henry NL, Loprinzi CL, Flynn PJ, Mitchell EP, Fisch MJ, Sparano JA, Wagner LI. A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11. Clin Cancer Res. 2024 Jul 1; 30 (13):2709-2718
    View PubMed
  5. McBane RD 2nd, Loprinzi CL, Zemla T, Tafur A, Sanfilippo K, Liu JJ, Garcia DA, Heun J, Gundabolu K, Onitilo AA, Perepu U, Drescher MR, Henkin S, Houghton D, Ashrani A, Billett H, McCue SA, Lee MK, Le-Rademacher JG, Wysokinski WE, EVE trial investigators. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial. J Thromb Haemost. 2024 Jun; 22 (6):1704-1714 Epub 2024 Mar 25
    View PubMed
  6. Muniz M, Loprinzi CL, Orme JJ, Koch RM, Mahmoud AM, Kase AM, Riaz IB, Andrews JR, Thorpe MP, Johnson GB, Kendi AT, Kwon ED, Nauseef JT, Morgans AK, Sartor O, Childs DS. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going. Cancer Treat Rev. 2024 Jun; 127:102748 Epub 2024 Apr 30
    View PubMed
  7. Cathcart-Rake EJ, Steinert K, Smith D, Lewis-Peters S, Giridhar K, Novotny P, Dauer D, O'Connor A, Thome S, Erickson MK, Friday BB, Loprinzi CL. Rose geranium in sesame oil nasal spray to improve nasal vestibulitis symptoms: a randomized controlled trial. Support Care Cancer. 2024 May 24; 32 (6):379
    View PubMed
  8. Mannion S, Higgins A, Larson N, Stewart EA, Khan Z, Shenoy C, Nichols HB, Su HI, Partridge AH, Loprinzi CL, Couch F, Olson JE, Ruddy KJ. Prevalence and impact of fertility concerns in young women with breast cancer. Sci Rep. 2024 Feb 22; 14 (1):4418
    View PubMed
  9. Childs DS, Novotny PJ, Marell PS, Ruddy KJ, Loprinzi CL. Hot flash clinical trial baseline measurements: how long is needed? BMJ Support Palliat Care. 2024 Jan 8; 13 (e3):e1110-e1116 Epub 2024 Jan 08
    View PubMed
  10. Smith EML, Cho Y, Hillman S, Scott MR, Harlos E, Wills R, Loprinzi C, Wilson CM, Zahrieh D. Patient-targeted education (ePRO-E) to increase ePRO intent within an Alliance clinical trial (A221805-SI1). JNCI Cancer Spectr. 2024 Jan 4; 8 (1)
    View PubMed
  11. Jahan N, Cathcart-Rake E, Vierkant RA, Larson N, Loprinzi C, O'Sullivan CC, Faubion S, Kuhle C, Vencill JA, Couch F, Olson JE, Ruddy KJ. Sexual Dysfunction in Patients With Metastatic Breast Cancer. Clin Breast Cancer. 2024 Jan; 24 (1):72-78.e4 Epub 2023 Oct 01
    View PubMed
  12. Hazim A, Nhola LF, Kailash V, Zhang S, Sandhu NP, Lerman A, Loprinzi CL, Ruddy KJ, Villarraga HR, Lewis B, Herrmann J. Changes in vascular function and correlation with cardiotoxicity in women with newly diagnosed breast cancer undergoing HER2-directed therapy with and without anthracycline/cyclophosphamide. Eur Heart J Open. 2024 Jan; 4 (1):oead130 Epub 2023 Dec 08
    View PubMed
  13. Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, Cherian M, Williams N, Sudheendra P, Wesolowski R, Sardesai S, Lustberg M, Loprinzi CL, Ruddy KJ, Cathcart-Rake E, Trovato S, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients. Support Care Cancer. 2023 Nov 22; 31 (12):717
    View PubMed
  14. Tawfik B, Dayao ZR, Brown-Glaberman UA, Pankratz VS, Lafky JM, Loprinzi CL, Barton DL. A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2. Support Care Cancer. 2023 Oct 17; 31 (12):637
    View PubMed
  15. Roeland EJ, Bohlke K, Baracos VE, Smith TJ, Loprinzi CL, Cancer Cachexia Expert Panel. Cancer Cachexia: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2023 Sep 1; 41 (25):4178-4179 Epub 2023 July 12
    View PubMed
  16. Marell PS, Vierkant RA, Olson JE, Herrmann J, Larson NL, Lebrasseur NK, D'Andre SD, Ehlers DK, Stan DL, Cheville AL, Barksdale T, Loprinzi CL, Couch FJ, Ruddy KJ. Changes in amount and intensity of physical activity over time in breast cancer survivors. JNCI Cancer Spectr. 2023 Aug 31; 7 (5)
    View PubMed
  17. Navari RM, Le-Rademacher J, Smieliauskas F, Ruddy KJ, James Saphner T, Liu H, Harlos E, Onitilo AA, Giridhar K, Paul Singh P, Reddy PS, Chow S, Kruter F, Raptis G, Loprinzi CL. Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602). Oncologist. 2023 Aug 3; 28 (8):722-729
    View PubMed
  18. Loprinzi CL, Novotny P, Ruddy KJ, Jatoi A, Le-Rademacher J, Ehlers SL, Cathcart-Rake E, Lee M. Measuring symptoms and toxicities: a 35-year experience. Support Care Cancer. 2023 Jul 27; 31 (8):495 Epub 2023 July 27
    View PubMed
  19. Smith TJ, Wang EJ, Loprinzi CL. Cutaneous Electroanalgesia for Relief of Chronic and Neuropathic Pain. N Engl J Med. 2023 Jul 13; 389 (2):158-164
    View PubMed
  20. Cathcart-Rake EJ, Zahrieh D, Smith D, Young S, McCue S, O'Connor A, Thome S, Lacouture M, Register T, Piens J, Friday BB, Loprinzi CL. A five arm natural history study of nasal vestibulitis. Cancer Med. 2023 Apr; 12 (8):9650-9654 Epub 2023 Apr 05
    View PubMed
  21. Rose L, Lustberg M, Ruddy KJ, Cathcart-Rake E, Loprinzi C, Dulmage B. Hair loss during and after breast cancer therapy. Support Care Cancer. 2023 Feb 24; 31 (3):186
    View PubMed
  22. Ruddy KJ, Zahrieh D, He J, Waechter B, Holleran JL, Lewis LD, Chow S, Beumer J, Weiss M, Trikalinos N, Faller B, Lustberg M, Rugo HS, Loprinzi C. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). Semin Oncol. 2023 Feb-Apr; 50 (1-2):7-10 Epub 2023 Jan 17
    View PubMed
  23. Storandt MH, Durani U, Stan D, Larson N, Loprinzi C, Couch F, Olson JE, Khera N, Ruddy KJ. Financial hardship in breast cancer survivors: a prospective analysis of change in financial concerns over time. Support Care Cancer. 2022 Dec 19; 31 (1):62
    View PubMed
  24. D'Andre SD, Bauer BA, Hofmann MB, Burckhard JL, Montane HN, Loprinzi CL. Dietary supplement use and recommendations for discontinuation in an integrative oncology clinic. Support Care Cancer. 2022 Dec 16; 31 (1):40
    View PubMed
  25. Mao JJ, Ismaila N, Bao T, Barton D, Ben-Arye E, Garland EL, Greenlee H, Leblanc T, Lee RT, Lopez AM, Loprinzi C, Lyman GH, MacLeod J, Master VA, Ramchandran K, Wagner LI, Walker EM, Bruner DW, Witt CM, Bruera E. Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline. J Clin Oncol. 2022 Dec 1; 40 (34):3998-4024 Epub 2022 Sept 19
    View PubMed
  26. Childs DS, Helfinstine DA Jr, Sangaralingham L, Orme JJ, O'Sullivan CC, Loprinzi CL, Ruddy KJ. Slow Uptake of an Effective Therapy: Patterns of Olanzapine Prescribing for Those Receiving Highly Emetogenic Chemotherapy. JCO Oncol Pract. 2022 Dec; 18(12):e1953-e1960. Epub 2022 Oct 31.
    View PubMed
  27. Chan A, Elsayed A, Ng DQ, Ruddy K, Loprinzi C, Lustberg M. A global survey on the utilization of cryotherapy and compression therapy for the prevention of chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2022 Dec; 30 (12):10001-10007 Epub 2022 Oct 10
    View PubMed
  28. Davis M, Loprinzi C. Pregabalin for chemotherapy-induced neuropathy: background and rationale for further study. Support Care Cancer. 2022 Nov; 30 (11):8845-8853 Epub 2022 Aug 11
    View PubMed
  29. Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski RT, Curigliano G, Felip E, Ferreira AR, Ganz PA, Hegarty J, Jeon J, Johansen C, Joly F, Jordan K, Koczwara B, Lagergren P, Lambertini M, Lenihan D, Linardou H, Loprinzi C, Partridge AH, Rauh S, Steindorf K, van der Graaf W, van de Poll-Franse L, Pentheroudakis G, Peters S, Pravettoni G. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Ann Oncol. 2022 Nov; 33 (11):1119-1133 Epub 2022 Aug 10
    View PubMed
  30. Marell PS, Vierkant RA, Olson JE, Herrmann J, Larson N, LeBrasseur NK, D'Andre SD, Cheville AL, Barksdale T, Loprinzi CL, Couch F, Ruddy KJ. Factors Associated With Physical Activity Levels in Patients With Breast Cancer. Oncologist. 2022 Oct 1; 27 (10):e811-e814
    View PubMed
  31. Karam D, Vierkant RA, Ehlers S, Freedman RA, Austin J, Khanani S, Larson NL, Loprinzi CL, Couch F, Olson JE, Ruddy KJ. Surveillance mammography in older breast cancer survivors: Current practice patterns and patient perceptions. J Geriatr Oncol. 2022 Sep; 13 (7):1038-1042 Epub 2022 July 16
    View PubMed
  32. Zahrieh D, Satele D, Smith EML, Loprinzi CL, Le-Rademacher J. Temporal, Location- and Symptom-Specific Likelihood of Patient-Reported Sensory Symptoms Related to Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in Patients Receiving Oxaliplatin for Three Months. Cancers (Basel). 2022 Feb 25; 14 (5)
    View PubMed
  33. Porter AB, Liu H, Kohli S, Cerhan JL, Sloan J, McMurray RP, Le-Rademacher J, Loprinzi CL, Villano JL, Kizilbash SH, Mehta MP, Jaeckle KA, Brown PD. Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Feb 1; 8 (2):259-267
    View PubMed
  34. Quick AM, Hundley A, Evans C, Stephens JA, Ramaswamy B, Reinbolt RE, Noonan AM, Van Deusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Faubion SS, Loprinzi CL, Lustberg MB. Long-Term Follow-Up of Fractional CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors. J Clin Med. 2022 Jan 31; 11 (3)
    View PubMed
  35. Hertz DL, Dockter TJ, Satele DV, Loprinzi CL, Le-Rademacher J. Neuropathy severity at the time of oxaliplatin treatment alteration in patients with colon cancer (Alliance A151912). Support Care Cancer. 2021 Dec; 29 (12):7855-7863 Epub 2021 June 27
    View PubMed
  36. Cathcart-Rake EJ, Zahrieh D, Smith D, Young S, McCue S, O'Connor A, Thome S, Lacouture M, Register T, Piens J, Friday BB, Loprinzi CL. Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study. Support Care Cancer. 2021 Nov; 29 (11):6253-6258 Epub 2021 Apr 13
    View PubMed
  37. He J, Perez DG, Le-Rademacher JL, Dodge A, Enck P, Loprinzi CL, Zahrieh D. Does the placebo effect on hot flashes depend on the placebo dose? Support Care Cancer. 2021 Nov; 29 (11):6741-6749 Epub 2021 May 11
    View PubMed
  38. Hertz DL, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, McGlown SM, Chan A, Grech LB, Loprinzi CL, Ruddy KJ, Lustberg M. Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treat Rev. 2021 Sep; 99:102241 Epub 2021 June 09
    View PubMed
  39. Patel SR, Herrmann J, Vierkant RA, Olson JE, Couch FJ, Hazim A, Sloan JA, Loprinzi CL, Ruddy KJ. N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors. J Clin Med. 2021 Jul 27; 10 (15) Epub 2021 July 27
    View PubMed
  40. Mayo SJ, Lustberg M, M Dhillon H, Nakamura ZM, Allen DH, Von Ah D, C Janelsins M, Chan A, Olson K, Tan CJ, Toh YL, Oh J, Grech L, Cheung YT, Subbiah IM, Petranovic D, D'Olimpio J, Gobbo M, Koeppen S, Loprinzi CL, Pang L, Shinde S, Ntukidem O, Peters KB. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. Support Care Cancer. 2021 Jun; 29 (6):2821-2840 Epub 2020 Nov 24
    View PubMed
  41. Childs DS, Le-Rademacher JG, McMurray R, Bendel M, O'Neill C, Smith TJ, Loprinzi CL. Randomized Trial of Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy: Crossover Analysis. J Pain Symptom Manage. 2021 Jun; 61 (6):1247-1253 Epub 2020 Nov 27
    View PubMed
  42. Perez DG, Loprinzi C, Ruddy KJ. Lifestyle Factors Can Lead to Multiple Cancers Over a Lifetime-Here We Go Again. JAMA Oncol 2021 Apr 1; 7 (4):505-506
    View PubMed
  43. Adjei AA, Lopez CL, Schaid DJ, Sloan JA, Le-Rademacher JG, Loprinzi CL, Norman AD, Olson JE, Couch FJ, Beutler AS, Vachon CM, Ruddy KJ. Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study. Cancers (Basel). 2021 Mar 3; 13 (5) Epub 2021 Mar 03
    View PubMed
  44. Adjei AA, Lopez CL, Schaid DJ, Sloan JA, Le-Rademacher JG, Loprinzi CL, Norman AD, Olson JE, Couch FJ, Beutler AS, Vachon CM, Ruddy KJ. Genetic Variations and Health-Related Quality of Life (HRQOL): A Genome-Wide Study Approach. Cancers (Basel). 2021 Feb 10; 13 (4)
    View PubMed
  45. Albany C, Dockter T, Wolfe E, Le-Rademacher J, Wagner-Johnston N, Einhorn L, Lafky JM, Smith E, Pachman D, Staff N, Ma C, Loprinzi CL, Costello BA. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). Support Care Cancer. 2021 Feb; 29 (2):833-840 Epub 2020 June 04
    View PubMed
  46. Quick AM, Zvinovski F, Hudson C, Hundley A, Evans C, Stephens JA, Arthur E, Ramaswamy B, Reinbolt RE, Noonan AM, VanDeusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Faubion SS, Loprinzi CL, Lustberg MB. Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy. Menopause. 2021 Feb 1; 28 (6):642-649 Epub 2021 Feb 01
    View PubMed
  47. Quick AM, Dockter T, Le-Rademacher J, Salani R, Hudson C, Hundley A, Terstriep S, Streicher L, Faubion S, Loprinzi CL, Coleman JS, Wang KC, Lustberg M. Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. Maturitas. 2021 Feb; 144:37-44 Epub 2020 Dec 02
    View PubMed
  48. Naughton MJ, Liu H, Seisler DK, Le-Rademacher J, Armer JM, Oliveri JM, Sloan JA, Hock K, Schwartz M, Unzeitig G, Melnik M, Yee LD, Fleming GF, Taylor JR, Loprinzi C, Paskett ED. Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients. Cancer. 2021 Jan 15; 127 (2):300-309 Epub 2020 Oct 20
    View PubMed
  49. Paskett ED, Le-Rademacher J, Oliveri JM, Liu H, Seisler DK, Sloan JA, Armer JM, Naughton MJ, Hock K, Schwartz M, Unzeitig G, Melnik M, Yee LD, Fleming GF, Taylor JR, Loprinzi C. A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance). Cancer. 2021 Jan 15; 127 (2):291-299 Epub 2020 Oct 20
    View PubMed
  50. Cathcart-Rake E, Novotny P, Leon-Ferre R, Le-Rademacher J, Storrick EM, Adjei AA, Terstriep S, Glaser R, Giuliano A, Mitchell WR, Page S, Austin C, Deming RL, Ferreira MA, Lafky JM, Birrell SN, Loprinzi CL. A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102. Support Care Cancer. 2021 Jan; 29 (1):387-396 Epub 2020 May 06
    View PubMed
  51. D'Andre S, McAllister S, Nagi J, Giridhar KV, Ruiz-Macias E, Loprinzi C. Topical Cannabinoids for Treating Chemotherapy-Induced Neuropathy: A Case Series. Integr Cancer Ther. 2021 Jan-Dec; 20:15347354211061739
    View PubMed
  52. Patel SR, Zayas J, Medina-Inojosa JR, Loprinzi C, Cathcart-Rake EJ, Bhagra A, Olson JE, Couch FJ, Ruddy KJ. Real-World Experiences With Yoga on Cancer-Related Symptoms in Women With Breast Cancer. Glob Adv Health Med. 2021; 10:2164956120984140 Epub 2021 Jan 08
    View PubMed
  53. Cathcart-Rake EJ, Smith D, Zahrieh D, Loprinzi CL. Rose geranium in sesame oil nasal spray: a treatment for nasal vestibulitis? BMJ Support Palliat Care. 2020 Dec; 10 (4):411-413 Epub 2018 Sept 26
    View PubMed
  54. Barton DL, Atherton PJ, Satele DV, Qin R, Dakhil S, Pipe T, Hobday T, Fee-Schroeder K, Loprinzi CL. A randomized phase II trial evaluating two non-pharmacologic interventions in cancer survivors for the treatment of sleep-wake disturbances: NCCTG N07C4 (Alliance). Support Care Cancer. 2020 Dec; 28 (12):6085-6094 Epub 2020 Apr 19
    View PubMed
  55. Zayas J, Ruddy KJ, Olson JE, Couch FJ, Bauer BA, Mallory MJ, Yang P, Zahrieh D, Athreya AP, Loprinzi CL, Cathcart-Rake EJ. Real-world experiences with acupuncture among breast cancer survivors: a cross-sectional survey study. Support Care Cancer. 2020 Dec; 28 (12):5833-5838 Epub 2020 Apr 06
    View PubMed
  56. Corn BW, Feldman D, Schapira L, Steensma DP, Loprinzi CL, Bian J. Oncologists' Reluctance to Use the Terms Hope and Cure: A Bibliometric Analysis of Articles From Two High-Impact Oncology Journals. JNCI Cancer Spectr. 2020 Dec; 4 (6):pkaa065 Epub 2020 Aug 14
    View PubMed
  57. Roeland EJ, Loprinzi CL. Reply to O. Huillard et al. J Clin Oncol 2020 Nov 10; 38 (32):3819 Epub 2020 Sept 18
    View PubMed
  58. Gupta A, Henry NL, Loprinzi CL. Management of Aromatase Inhibitor-Induced Musculoskeletal Symptoms. JCO Oncol Pract. 2020 Nov; 16 (11):733-739 Epub 2020 Aug 11
    View PubMed
  59. Loprinzi CL, Le-Rademacher JG, Navari RM. The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting-Reply. JAMA Oncol 2020 Nov 1; 6 (11):1812-1813
    View PubMed
  60. Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020 Oct 1; 38 (28):3325-3348 Epub 2020 July 14
    View PubMed
  61. Sheehan MT, Wermers RA, Jatoi A, Loprinzi CL, Onitilo AA. Oral cinacalcet responsiveness in non-parathyroid hormone mediated hypercalcemia of malignancy. Med Hypotheses. 2020 Oct; 143:110149 Epub 2020 July 30
    View PubMed
  62. Schunemann HJ, Ventresca M, Crowther M, Briel M, Zhou Q, Noble S, Macbeth F, Griffiths G, Garcia D, Lyman GH, Di Nisio M, Iorio A, Mbuagbaw L, Neumann I, van Es N, Brouwers M, Guyatt G, Streiff MB, Marcucci M, Baldeh T, Florez ID, Alma OG, Solh Z, Bossuyt PM, Kahale LA, Ageno W, Bozas G, Buller HR, Lebeau B, Lecumberri R, Loprinzi C, McBane R, Sideras K, Maraveyas A, Pelzer U, Perry J, Klerk C, Agnelli G, Akl EA. Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. Lancet Haematol. 2020 Oct; 7 (10):e746-e755
    View PubMed
  63. Huang KM, Leblanc AF, Uddin ME, Kim JY, Chen M, Eisenmann ED, Gibson AA, Li Y, Hong KW, DiGiacomo D, Xia SH, Alberti P, Chiorazzi A, Housley SN, Cope TC, Sprowl JA, Wang J, Loprinzi CL, Noonan A, Lustberg MB, Cavaletti G, Pabla N, Hu S, Sparreboom A. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. J Clin Invest. 2020 Sep 1; 130 (9):4601-4606
    View PubMed
  64. Quick AM, Zvinovski F, Hudson C, Hundley A, Evans C, Suresh A, Stephens JA, Arthur E, Ramaswamy B, Reinbolt RE, Noonan AM, VanDeusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Smith KL, Faubion SS, Loprinzi CL, Lustberg MB. Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors. Support Care Cancer. 2020 Aug; 28 (8):3669-3677 Epub 2019 Dec 06
    View PubMed
  65. van Es N, Ventresca M, Di Nisio M, Zhou Q, Noble S, Crowther M, Briel M, Garcia D, Lyman GH, Macbeth F, Griffiths G, Iorio A, Mbuagbaw L, Lawrence M, Neumann I, Brozek J, Guyatt G, Streiff MB, Baldeh T, Florez ID, Gurunlu Alma O, Agnelli G, Ageno W, Marcucci M, Bozas G, Zulian G, Maraveyas A, Lebeau B, Lecumberri R, Sideras K, Loprinzi C, McBane R, Pelzer U, Riess H, Solh Z, Perry J, Kahale LA, Bossuyt PM, Klerk C, Buller HR, Akl EA, Schunemann HJ, IPDMA Heparin Use in Cancer Patients Research Group. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. J Thromb Haemost. 2020 Aug; 18 (8):1940-1951 Epub 2020 July 08
    View PubMed
  66. Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, Fallon M, Herrstedt J, Lau H, Platek M, Rugo HS, Schnipper HH, Smith TJ, Tan W, Loprinzi CL. Management of Cancer Cachexia: ASCO Guideline. J Clin Oncol. 2020 Jul 20; 38 (21):2438-2453 Epub 2020 May 20
    View PubMed
  67. Lakin JR, Brannen EN, Tulsky JA, Paasche-Orlow MK, Lindvall C, Chang Y, Gundersen DA, El-Jawahri A, Volandes A. Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly (ACP-PEACE): the study protocol for a pragmatic stepped-wedge trial of older patients with cancer. BMJ Open. 2020 Jul 14; 10 (7):e040999 Epub 2020 July 14
    View PubMed
  68. Lakin JR, Brannen EN, Tulsky JA, Paasche-Orlow MK, Lindvall C, Chang Y, Gundersen DA, El-Jawahri A, Volandes A. Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly (ACP-PEACE): the study protocol for a pragmatic stepped-wedge trial of older patients with cancer. BMJ Open. 2020 Jul 14; 10 (7):e040999 Epub 2020 July 14
    View PubMed
  69. Temel JS, Sloan J, Zemla T, Greer JA, Jackson VA, El-Jawahri A, Kamdar M, Kamal A, Blinderman CD, Strand J, Zylla D, Daugherty C, Furqan M, Obel J, Razaq M, Roeland EJ, Loprinzi C. Multisite, Randomized Trial of Early Integrated Palliative and Oncology Care in Patients with Advanced Lung and Gastrointestinal Cancer: Alliance A221303. J Palliat Med. 2020 Jul; 23 (7):922-929 Epub 2020 Feb 07
    View PubMed
  70. Salgado TM, Liu J, Reed HL, Quinn CS, Syverson JG, Le-Rademacher J, Lopez CL, Beutler AS, Loprinzi CL, Vangipuram K, Smith EML, Henry NL, Farris KB, Hertz DL. Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study. Breast. 2020 Jun; 51:21-28 Epub 2020 Mar 03
    View PubMed
  71. Navari RM, Pywell CM, Le-Rademacher JG, White P, Dodge AB, Albany C, Loprinzi CL. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial. JAMA Oncol. 2020 Jun 1; 6 (6):895-899
    View PubMed
  72. Navari RM, Loprinzi CL. Olanzapine is an effective antiemetic agent. Ann Palliat Med 2020 May; 9 (3):628-630
    View PubMed
  73. Correa MEP, Cheng KKF, Chiang K, Kandwal A, Loprinzi CL, Mori T, Potting C, Rouleau T, Toro JJ, Ranna V, Vaddi A, Peterson DE, Bossi P, Lalla RV, Elad S. Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2020 May; 28 (5):2449-2456 Epub 2019 Dec 14
    View PubMed
  74. Tofthagen CS, Cheville AL, Loprinzi CL. The Physical Consequences of Chemotherapy-Induced Peripheral Neuropathy. Curr Oncol Rep. 2020 Apr 22; 22 (5):50
    View PubMed
  75. Le-Rademacher JG, Lopez CL, Kanwar R, Major-Elechi B, Abyzov A, Banck MS, Therneau TM, Sloan JA, Loprinzi CL, Beutler AS. Neurological safety of oxaliplatin in patients with uncommon variants in Charcot-Marie-tooth disease genes. J Neurol Sci. 2020 Apr 15; 411:116687 Epub 2020 Jan 14
    View PubMed
  76. Zayas J, Ruddy KJ, Olson JE, Couch FJ, Bauer BA, Mallory MD, Yang P, Zahrieh D, Athreya A, Loprinzi CL, Cathcart-Rake EJ. Real-world experiences with acupuncture among breast cancer survivors: a cross-sectional survey study Support Care Cancer. 2020.
    View PubMed
  77. Loprinzi C, Le-Rademacher JG, Majithia N, McMurray RP, O'Neill CR, Bendel MA, Beutler A, Lachance DH, Cheville A, Strick DM, Black DF, Tilburt JC, Smith TJ. Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial. Support Care Cancer. 2020 Mar; 28 (3):1183-1197 Epub 2019 June 17
    View PubMed
  78. Leon-Ferre RA, Novotny PJ, Wolfe EG, Faubion SS, Ruddy KJ, Flora D, Dakhil CSR, Rowland KM, Graham ML, Le-Lindqwister N, Smith TJ, Loprinzi CL. Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603). JNCI Cancer Spectr. 2020 Feb; 4 (1):pkz088 Epub 2019 Oct 21
    View PubMed
  79. McBane RD 2nd, Loprinzi CL, Ashrani A, Lenz CJ, Houghton D, Zemla T, Le-Rademacher JG, Wysokinski WE. Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial. Eur J Haematol. 2020 Feb; 104 (2):88-96 Epub 2019 Nov 11
    View PubMed
  80. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020 Feb; 18 (2):411-421 Epub 2019 Nov 28
    View PubMed
  81. Smith TJ, Razzak AR, Blackford AL, Ensminger J, Saiki C, Longo-Schoberlein D, Loprinzi CL. A Pilot Randomized Sham-Controlled Trial of MC5-A Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN). J Palliat Care. 2020 Jan; 35 (1):53-58 Epub 2019 Feb 03
    View PubMed
  82. Loprinzi CL, Hershman DL, Staff N. Neuronal Protection for Chemotherapy Neuropathy Prevention? J Natl Cancer Inst 2020 Jan 1; 112 (1):3-4
    View PubMed
  83. Fuentes HE, McBane RD 2nd, Wysokinski WE, Tafur AJ, Loprinzi CL, Murad MH, Riaz IB. Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous Thromboembolism: A Systematic Review and Network Meta-analysis. Mayo Clin Proc. 2019 Dec; 94 (12):2444-2454 Epub 2019 Nov 02
    View PubMed
  84. Guru SD, Loprinzi CL, Yan E, Hoskin TL, Jakub JW. Contralateral Axillary Metastases in Breast Cancer: Stage IV Disease or a Locoregional Event? Am Surg. 2019 Dec 1; 85 (12):1391-1396
    View PubMed
  85. Ruddy KJ, Le-Rademacher J, Lacouture ME, Wilkinson M, Onitilo AA, Vander Woude AC, Grosse-Perdekamp MT, Dockter T, Tan AD, Beutler A, Loprinzi CL. Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial. Breast. 2019 Dec; 48:89-97 Epub 2019 Sept 19
    View PubMed
  86. Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB. Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy. Clin Cancer Res. 2019 Nov 1; 25 (21):6295-6301 Epub 2019 May 23
    View PubMed
  87. Leon Ferre RA, Novotny PJ, Wolfe EG, Faubion SS, Ruddy KJ, Flora , Daniel, Dakhil , Christopher S. R., Rowland , Kendrith M., Graham , Mark L., Le-Lindqwister , Nguyet, Smith , Thomas J., Loprinzi CL. Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603) JNCI Cancer Spectrum. 2019; 4(1):pkz088.
  88. Vera J, Paludo J, Kottschade L, Brandt J, Yan Y, Block M, McWilliams R, Dronca R, Loprinzi C, Grothey A, Markovic SN. Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine. Support Care Cancer. 2019 Oct; 27 (10):3869-3875 Epub 2019 Feb 14
    View PubMed
  89. Chan A, Hertz DL, Morales M, Adams EJ, Gordon S, Tan CJ, Staff NP, Kamath J, Oh J, Shinde S, Pon D, Dixit N, D'Olimpio J, Dumitrescu C, Gobbo M, Kober K, Mayo S, Pang L, Subbiah I, Beutler AS, Peters KB, Loprinzi C, Lustberg MB. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. Support Care Cancer. 2019 Oct; 27 (10):3729-3737 Epub 2019 July 30
    View PubMed
  90. Smith EML, Zanville N, Kanzawa-Lee G, Donohoe C, Bridges C, Loprinzi C, Le-Rademacher J, Yang JJ. Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data. Support Care Cancer. 2019 Jul; 27 (7):2599-2608 Epub 2018 Nov 20
    View PubMed
  91. Dorsey SG, Kleckner IR, Barton D, Mustian K, O'Mara A, St Germain D, Cavaletti G, Danhauer SC, Hershman DL, Hohmann AG, Hoke A, Hopkins JO, Kelly KP, Loprinzi CL, McLeod HL, Mohile S, Paice J, Rowland JH, Salvemini D, Segal RA, Smith EL, Stevens WM, Janelsins MC. The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. J Natl Cancer Inst. 2019 Jun 1; 111 (6):531-537
    View PubMed
  92. Monfort SM, Pan X, Loprinzi CL, Lustberg MB, Chaudhari AMW. Exploring the Roles of Central and Peripheral Nervous System Function in Gait Stability: Preliminary Insights from Cancer Survivors. Gait Posture. 2019 Jun; 71:62-68 Epub 2019 Apr 06
    View PubMed
  93. Cheville AL, Moynihan T, Herrin J, Loprinzi C, Kroenke K. Effect of Collaborative Telerehabilitation on Functional Impairment and Pain Among Patients With Advanced-Stage Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 May 1; 5 (5):644-652
    View PubMed
  94. Smith EML, Banerjee T, Yang JJ, Bridges CM, Alberti P, Sloan JA, Loprinzi C. Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data. Cancer Nurs. 2019 May/Jun; 42 (3):179-189
    View PubMed
  95. Sio TT, Le-Rademacher JG, Leenstra JL, Loprinzi CL, Rine G, Curtis A, Singh AK, Martenson JA Jr, Novotny PJ, Tan AD, Qin R, Ko SJ, Reiter PL, Miller RC. Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial. JAMA. 2019 Apr 16; 321 (15):1481-1490
    View PubMed
  96. Monfort SM, Pan X, Loprinzi CL, Lustberg MB, Chaudhari AMW. Impaired Postural Control and Altered Sensory Organization During Quiet Stance Following Neurotoxic Chemotherapy: A Preliminary Study. Integr Cancer Ther. 2019 Jan-Dec; 18:1534735419828823
    View PubMed
  97. Cathcart-Rake E, Smith D, Zahrieh D, Jatoi A, Yang P, Loprinzi CL. Nasal vestibulitis: an under-recognized and under-treated side effect of cancer treatment? Support Care Cancer. 2018 Nov; 26 (11):3909-3914 Epub 2018 May 24
    View PubMed
  98. Herrmann J, Loprinzi C, Ruddy K. Building a Cardio-Onco-Hematology Program. Curr Oncol Rep. 2018 Sep 10; 20 (10):81 Epub 2018 Sept 10
    View PubMed
  99. Gewandter JS, Brell J, Cavaletti G, Dougherty PM, Evans S, Howie L, McDermott MP, O'Mara A, Smith AG, Dastros-Pitei D, Gauthier LR, Haroutounian S, Jarpe M, Katz NP, Loprinzi C, Richardson P, Lavoie-Smith EM, Wen PY, Turk DC, Dworkin RH, Freeman R. Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology. 2018 Aug 28; 91 (9):403-413 Epub 2018 July 27
    View PubMed
  100. Leal AD, Van Houten H, Sangaralingham L, Freedman RA, Jemal A, Neuman HB, Haddad TC, Mutter RW, Keegan THM, Mougalian SS, Loprinzi CL, Gross CP, Shah N, Ruddy KJ. Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens. Clin Breast Cancer. 2018 Aug; 18 (4):e513-e520 Epub 2017 Sept 22
    View PubMed
  101. O'Sullivan CC, Loprinzi CL, Haddad TC. Updates in the Evaluation and Management of Breast Cancer. Mayo Clin Proc. 2018 Jun; 93 (6):794-807
    View PubMed
  102. Shah A, Hoffman EM, Mauermann ML, Loprinzi CL, Windebank AJ, Klein CJ, Staff NP. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry. 2018 Jun; 89 (6):636-641 Epub 2018 Feb 08
    View PubMed
  103. Simmons B, Wysokinski W, Saadiq RA, Bott-Kitslaar D, Henkin S, Casanegra A, Lenz C, Daniels P, Bjarnason H, Vargas E, Hodge D, Holton SJ, Cerhan JR, Loprinzi C, McBane R 2nd. Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer-associated venous thromboembolism. Eur J Haematol. 2018 Apr 04. [Epub ahead of print]
    View PubMed
  104. Barton DL, Shuster LT, Dockter T, Atherton PJ, Thielen J, Birrell SN, Sood R, Griffin P, Terstriep SA, Mattar B, Lafky JM, Loprinzi CL. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Support Care Cancer. 2018 Apr; 26 (4):1335-1343 Epub 2017 Nov 21
    View PubMed
  105. O'Sullivan CC, Van Houten HK, Sangaralingham LR, Leal AD, Shinde S, Liu H, Ettinger D, Loprinzi CL, Ruddy KJ. Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy. J Natl Compr Canc Netw. 2018 Mar; 16 (3):294-299
    View PubMed
  106. Lustberg MB, Orchard TS, Reinbolt R, Andridge R, Pan X, Belury M, Cole R, Logan A, Layman R, Ramaswamy B, Wesolowski R, Berger M, Patterson E, Loprinzi C, Shapiro CL, Yee L. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain. Breast Cancer Res Treat. 2018 Feb; 167 (3):709-718 Epub 2017 Nov 03
    View PubMed
  107. Barton DL, Sloan JA, Shuster LT, Gill P, Griffin P, Flynn K, Terstriep SA, Rana FN, Dockter T, Atherton PJ, Tsai M, Sturtz K, Lafky JM, Riepl M, Thielen J, Loprinzi CL. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer. 2018 Feb; 26 (2):643-650 Epub 2017 Sept 18
    View PubMed
  108. Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. Clin Cancer Res. 2017 Nov 15; 23(22):6823-6832. Epub 2017 Sep 05.
    View PubMed
  109. Ruddy KJ, Navari RM, Loprinzi CL. Thalidomide: Rebirth of a Gestational Antiemetic? J Clin Oncol 2017 Nov 1; 35 (31):3523-3524 Epub 2017 Sept 05
    View PubMed
  110. Gilligan T, Coyle N, Frankel RM, Berry DL, Bohlke K, Epstein RM, Finlay E, Jackson VA, Lathan CS, Loprinzi CL, Nguyen LH, Seigel C, Baile WF. Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline. J Clin Oncol. 2017 Nov 1; 35 (31):3618-3632 Epub 2017 Sept 11
    View PubMed
  111. Le-Rademacher J, Kanwar R, Seisler D, Pachman DR, Qin R, Abyzov A, Ruddy KJ, Banck MS, Lavoie Smith EM, Dorsey SG, Aaronson NK, Sloan J, Loprinzi CL, Beutler AS. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. Support Care Cancer. 2017 Nov; 25 (11):3537-3544 Epub 2017 June 20
    View PubMed
  112. Beutler AS, Majithia N, Loprinzi CL. The past and future of 'reported outcomes' in studies on chemotherapy neuropathy. Ann Oncol 2017 Nov 1; 28 (11):2631-2632
    View PubMed
  113. Pachman DR, Dockter T, Zekan PJ, Fruth B, Ruddy KJ, Ta LE, Lafky JM, Dentchev T, Le-Lindqwister NA, Sikov WM, Staff N, Beutler AS, Loprinzi CL. A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I. Support Care Cancer. 2017 Nov; 25 (11):3407-3416 Epub 2017 May 27
    View PubMed
  114. McBane Ii R, Loprinzi CL, Ashrani A, Perez-Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Le-Rademacher JG, Wysokinski WE. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial. Thromb Haemost. 2017 Oct 05; 117(10):1952-1961. Epub 2017 Aug 24.
    View PubMed
  115. Jatoi A, Steen PD, Atherton PJ, Moore DF, Rowland KM, Le-Lindqwister NA, Adonizio CS, Jaslowski AJ, Sloan J, Loprinzi C. A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial. Ann Oncol. 2017 Aug 1; 28 (8):1957-1963
    View PubMed
  116. Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M. NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017 Jul; 15 (7):883-893
    View PubMed
  117. Monfort SM, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton MJ, Loprinzi CL, Chaudhari AMW, Lustberg MB. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Res Treat. 2017 Jul; 164 (1):69-77 Epub 2017 Apr 03
    View PubMed
  118. Smith T, Cheville AL, Loprinzi CL, Longo-Schoberlein D. Scrambler Therapy for the Treatment of Chronic Post-Mastectomy Pain (cPMP). Cureus. 2017 Jun 21; 9 (6):e1378 Epub 2017 June 21
    View PubMed
  119. Le-Rademacher J, Hillman SL, Meyers J, Loprinzi CL, Limburg PJ, Mandrekar SJ. Statistical controversies in clinical research: Value of adverse events relatedness to study treatment: analyses of data from randomized double-blind placebo-controlled clinical trials. Ann Oncol. 2017 Jun 1; 28 (6):1183-1190
    View PubMed
  120. Himelstein AL, Loprinzi CL, Shapiro CL. Zoledronic Acid Dosing Interval for Metastatic Cancer-Reply. JAMA 2017 Apr 11; 317 (14):1478
    View PubMed
  121. Smith EM, Pang H, Ye C, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Le-Lindqwister N, Fadul CE, Loprinzi C, Shapiro CL, Alliance for Clinical Trials in Oncology. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601. Eur J Cancer Care (Engl). 2017 Mar; 26 (2) Epub 2015 Nov 25
    View PubMed
  122. Leon-Ferre R, Ruddy KJ, Staff NP, Loprinzi CL. Fit for Chemo: Nerves May Thank You. J Natl Cancer Inst 2017 Feb; 109 (2) Epub 2016 Oct 28
    View PubMed
  123. Leon-Ferre R, Ruddy KJ, Staff NP, Loprinzi CL. Fit for Chemo: Nerves May Thank You. J Natl Cancer Inst. 2017 Feb; 109(2). Epub 2016 Oct 28.
    View PubMed
  124. Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2017 Jan 3; 317 (1):48-58
    View PubMed
  125. Leon-Ferre RA, Majithia N, Loprinzi CL. Management of hot flashes in women with breast cancer receiving ovarian function suppression. Cancer Treat Rev. 2017 Jan; 52:82-90 Epub 2016 Dec 05
    View PubMed
  126. Pachman DR, Qin R, Seisler D, Smith EM, Kaggal S, Novotny P, Ruddy KJ, Lafky JM, Ta LE, Beutler AS, Wagner-Johnston ND, Staff NP, Grothey A, Dougherty PM, Cavaletti G, Loprinzi CL. Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer. 2016 Dec; 24 (12):5059-5068 Epub 2016 Aug 18
    View PubMed
  127. Majithia N, Loprinzi CL, Smith TJ. New Practical Approaches to Chemotherapy-Induced Neuropathic Pain: Prevention, Assessment, and Treatment. Oncology (Williston Park). 2016 Nov 15; 30 (11):1020-9
    View PubMed
  128. Sio TT, Atherton PJ, Birckhead BJ, Schwartz DJ, Sloan JA, Seisler DK, Martenson JA, Loprinzi CL, Griffin PC, Morton RF, Anders JC, Stoffel TJ, Haselow RE, Mowat RB, Wittich MA, Bearden JD 3rd, Miller RC. Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer. 2016 Sep; 24 (9):3847-55 Epub 2016 Apr 14
    View PubMed
  129. Faubion SS, Loprinzi CL, Ruddy KJ. Management of Hormone Deprivation Symptoms After Cancer. Mayo Clin Proc. 2016 Aug; 91 (8):1133-46
    View PubMed
  130. Miller RC, Petereit DG, Sloan JA, Liu H, Martenson JA, Bearden JD 3rd, Sapiente R, Seeger GR, Mowat RB, Liem B, Iott MJ, Loprinzi CL, Alliance for Clinical Trials in Oncology. N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Jul 15; 95 (4):1168-74 Epub 2016 Apr 23
    View PubMed
  131. Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Jul 14; 375 (2):134-42
    View PubMed
  132. Monfort SM, Pan X, Patrick R, Singaravelu J, Loprinzi CL, Lustberg MB, Chaudhari AMW. Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot study. Gait Posture. 2016 Jul; 48:237-242 Epub 2016 June 14
    View PubMed
  133. Kottschade L, Novotny P, Lyss A, Mazurczak M, Loprinzi C, Barton D. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance). Support Care Cancer. 2016 Jun; 24 (6):2661-7 Epub 2016 Jan 15
    View PubMed
  134. Majithia N, Smith TJ, Coyne PJ, Abdi S, Pachman DR, Lachance D, Shelerud R, Cheville A, Basford JR, Farley D, O'Neill C, Ruddy KJ, Sparadeo F, Beutler A, Loprinzi CL. Scrambler Therapy for the management of chronic pain. Support Care Cancer. 2016 Jun; 24 (6):2807-14 Epub 2016 Apr 04
    View PubMed
  135. Bott-Kitslaar DM, Saadiq RA, McBane RD, Loprinzi CL, Ashrani AA, Ransone TR, Wolfgram AA, Berentsen MM, Wysokinski WE. Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry. Am J Med. 2016 Jun; 129 (6):615-9 Epub 2016 Jan 18
    View PubMed
  136. Thanarajasingam G, Atherton PJ, Novotny PJ, Loprinzi CL, Sloan JA, Grothey A. Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Lancet Oncol. 2016 May; 17 (5):663-70 Epub 2016 Apr 12
    View PubMed
  137. Boora GK, Kanwar R, Kulkarni AA, Abyzov A, Sloan J, Ruddy KJ, Banck MS, Loprinzi CL, Beutler AS. Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). Cancer Med. 2016 Apr; 5 (4):631-9 Epub 2016 Jan 14
    View PubMed
  138. Navari RM, Nagy CK, Le-Rademacher J, Loprinzi CL. Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol. 2016 Apr; 14: (4)141-7.
    View PubMed
  139. Kadakia KC, Loprinzi CL, Atherton PJ, Fee-Schroeder KC, Sood A, Barton DL. Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes. Support Care Cancer. 2016 Mar; 24 (3):1061-9 Epub 2015 Aug 08
    View PubMed
  140. Majithia N, Temkin SM, Ruddy KJ, Beutler AS, Hershman DL, Loprinzi CL. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Support Care Cancer. 2016 Mar; 24 (3):1439-47 Epub 2015 Dec 19
    View PubMed
  141. Majithia N, Atherton PJ, Lafky JM, Wagner-Johnston N, Olson J, Dakhil SR, Perez EA, Loprinzi CL, Hines SL. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. Support Care Cancer. 2016 Mar; 24 (3):1219-26 Epub 2015 Aug 23
    View PubMed
  142. Zimmerman C, Atherton PJ, Pachman D, Seisler D, Wagner-Johnston N, Dakhil S, Lafky JM, Qin R, Grothey A, Loprinzi CL. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer. 2016 Mar; 24 (3):1071-8 Epub 2015 Aug 08
    View PubMed
  143. Shinde SS, Seisler D, Soori G, Atherton PJ, Pachman DR, Lafky J, Ruddy KJ, Loprinzi CL. Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial. Support Care Cancer. 2016 Feb; 24 (2):547-553 Epub 2015 July 09
    View PubMed
  144. Smith TJ, Loprinzi CL, Cheville AL. Scrambler therapy for the treatment of chronic post-mastectomy pain (cPMP) in breast cancer survivors Journal of Clinical Oncology. 2016; 34 (26 Suppl):253
  145. Majithia N, Loprinzi CL, Smith TJ. New practical approaches to chemotherapy-induced neuropathic pain: Prevention, assessment, and treatment ONCOLOGY (United States). 2016; 30: (11)1020-9.
  146. Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S, Staff NP, Grothey A, Loprinzi CL. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). J Clin Oncol. 2015 Oct 20; 33 (30):3416-22 Epub 2015 Aug 17
    View PubMed
  147. Boora GK, Kulkarni AA, Kanwar R, Beyerlein P, Qin R, Banck MS, Ruddy KJ, Pleticha J, Lynch CA, Behrens RJ, Züchner S, Loprinzi CL, Beutler AS. Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). J Neurol Sci. 2015 Oct 15; 357(1-2):35-40. Epub 2015 Jun 27.
    View PubMed
  148. Steensma DP, Dakhil SR, Novotny PJ, Sloan JA, Johnson DB, Anderson DM, Mattar BI, Moore DF Jr, Nikcevich D, Loprinzi CL. A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia. Am J Hematol. 2015 Oct; 90: (10)877-81.
    View PubMed
  149. Pachman DR, Ruddy K, Sangaralingham LR, Grothey A, Shah ND, Beutler AS, Hubbard JM, Loprinzi CL. Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice. J Natl Compr Canc Netw. 2015 Sep; 13 (9):1097-101
    View PubMed
  150. Wagner-Johnston ND, Sloan JA, Liu H, Kearns AE, Hines SL, Puttabasavaiah S, Dakhil SR, Lafky JM, Perez EA, Loprinzi CL. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer. 2015 Aug 01; 121(15):2537-43. Epub 2015 Apr 30.
    View PubMed
  151. Dueck AC, Singh J, Atherton P, Liu H, Novotny P, Hines S, Loprinzi CL, Perez EA, Tan A, Burger K, Zhao X, Diekmann B, Sloan JA, Alliance for Clinical Trials in Oncology. Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance). Osteoporos Int. 2015 Jul; 26 (7):1971-7 Epub 2015 Mar 07
    View PubMed
  152. Steensma DP, Sasu BJ, Sloan JA, Tomita DK, Loprinzi CL. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia. Blood 2015 Jun 4; 125 (23):3669-71
    View PubMed
  153. Park H, Qin R, Smith TJ, Atherton PJ, Barton DL, Sturtz K, Dakhil SR, Anderson DM, Flynn K, Puttabasavaiah S, Le-Lindqwister NA, Padula GD, Loprinzi CL. North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause. 2015 Jun; 22 (6):627-32
    View PubMed
  154. Lewis MA, Zhao F, Jones D, Loprinzi CL, Brell J, Weiss M, Fisch MJ. Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study. J Pain Symptom Manage. 2015 Jun; 49 (6):1016-24 Epub 2015 Jan 14
    View PubMed
  155. Renfro LA, Grothey A, Kerr D, Haller DG, Andre T, Van Cutsem E, Saltz L, Labianca R, Loprinzi CL, Alberts SR, Schmoll H, Twelves C, Yothers G, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group. Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general populationdagger. Ann Oncol. 2015 May; 26 (5):950-958 Epub 2015 Feb 19
    View PubMed
  156. Pachman DR, Weisbrod BL, Seisler DK, Barton DL, Fee-Schroeder KC, Smith TJ, Lachance DH, Liu H, Shelerud RA, Cheville AL, Loprinzi CL. Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2015 Apr; 23 (4):943-51 Epub 2014 Sept 24
    View PubMed
  157. Jones D, Zhao F, Brell J, Lewis MA, Loprinzi CL, Weiss M, Fisch MJ. Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer. J Cancer Surviv. 2015 Mar; 9(1):1-10. Epub 2014 Jul 15.
    View PubMed
  158. Johnson C, Pankratz VS, Velazquez AI, Aakre JA, Loprinzi CL, Staff NP, Windebank AJ, Yang P. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. J Neurol Sci. 2015 Feb 15; 349 (1-2):124-8 Epub 2015 Jan 05
    View PubMed
  159. Ruddy KJ, Majithia N, Pachman DR, Beutler AS, Loprinzi CL. Chemotherapy-induced Neuropathy—Where Are We Now? Oncology & Hematology Review. 2015; 11(1):53-5.
  160. Hegerova LT, Leal AD, Grendahl DC, Seisler DK, Sorgatz KM, Anderson KJ, Hilger CR, Loprinzi CL. An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2015 Jan; 23 (1):55-9 Epub 2014 June 26
    View PubMed
  161. Kulkarni AA, Boora G, Kanwar R, Ruddy KJ, Banck MS, Le-Lindqwister N, Therneau TM, Loprinzi CL, Beutler AS. RWDD3 and TECTA variants not linked to paclitaxel induced peripheral neuropathy in North American trial Alliance N08C1. Acta Oncol 2015; 54 (8):1227-9 Epub 2014 Dec 31
    View PubMed
  162. Schneider BP, Hershman DL, Loprinzi C. Symptoms: Chemotherapy-Induced Peripheral Neuropathy. Adv Exp Med Biol. 2015; 862:77-87
    View PubMed
  163. Hershman DL, Loprinzi C, Schneider BP. Symptoms: Aromatase Inhibitor Induced Arthralgias. Adv Exp Med Biol. 2015; 862:89-100
    View PubMed
  164. Renfro LA, Grothey A, Xue Y, Saltz LB, Andre T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group. ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. J Natl Cancer Inst. 2014 Dec; 106 (12) Epub 2014 Oct 29
    View PubMed
  165. Pachman DR, Watson JC, Loprinzi CL. Therapeutic strategies for cancer treatment related peripheral neuropathies. Curr Treat Options Oncol. 2014 Dec; 15 (4):567-80
    View PubMed
  166. Barton DL, Thanarajasingam G, Sloan JA, Diekmann B, Fuloria J, Kottschade LA, Lyss AP, Jaslowski AJ, Mazurczak MA, Blair SC, Terstriep S, Loprinzi CL. Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer. 2014 Nov 15; 120 (22):3575-83 Epub 2014 July 09
    View PubMed
  167. Beutler AS, Kulkarni AA, Kanwar R, Klein CJ, Therneau TM, Qin R, Banck MS, Boora GK, Ruddy KJ, Wu Y, Smalley RL, Cunningham JM, Le-Lindqwister NA, Beyerlein P, Schroth GP, Windebank AJ, Zuchner S, Loprinzi CL. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann Neurol. 2014 Nov; 76 (5):727-37 Epub 2014 Sept 17
    View PubMed
  168. Hershman DL, Lacchetti C, Loprinzi CL. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2014 Nov; 10 (6):e421-e424
    View PubMed
  169. Pachman DR, Watson JC, Lustberg MB, Wagner-Johnston ND, Chan A, Broadfield L, Cheung YT, Steer C, Storey DJ, Chandwani KD, Paice J, Jean-Pierre P, Oh J, Kamath J, Fallon M, Strik H, Koeppen S, Loprinzi CL. Management options for established chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2014 Aug; 22 (8):2281-95 Epub 2014 May 31
    View PubMed
  170. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jun 20; 32 (18):1941-67 Epub 2014 Apr 14
    View PubMed
  171. Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, Watanaboonyakhet P, Weiss M, Adams PT, Dockter TJ, Loprinzi CL, Alliance for Clinical Trials in Oncology. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer. 2014 Jun 15; 120 (12):1890-7 Epub 2014 Mar 11
    View PubMed
  172. Kadakia KC, Rozell SA, Butala AA, Loprinzi CL. Supportive cryotherapy: a review from head to toe. J Pain Symptom Manage. 2014 Jun; 47 (6):1100-15 Epub 2013 Nov 07
    View PubMed
  173. Leenstra JL, Miller RC, Qin R, Martenson JA, Dornfeld KJ, Bearden JD, Puri DR, Stella PJ, Mazurczak MA, Klish MD, Novotny PJ, Foote RL, Loprinzi CL. Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]). J Clin Oncol. 2014 May 20; 32 (15):1571-7 Epub 2014 Apr 14
    View PubMed
  174. Leal AD, Kadakia KC, Looker S, Hilger C, Sorgatz K, Anderson K, Jacobson A, Grendahl D, Seisler D, Hobday T, Loprinzi CL. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer. 2014 May; 22 (5):1313-7 Epub 2014 Jan 09
    View PubMed
  175. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014 Apr 1; 32 (10):997-1005 Epub 2013 Dec 02
    View PubMed
  176. Johnson C, Pankratz VS, Velazquez AI, Aakre JA, Loprinzi CL, Staff NP, Windebank AJ, Yang P. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. J Neurol Sci. 2014; 349(1-2):124-8.
  177. Jones D, Zhao F, Brell J, Lewis MA, Loprinzi CL, Weiss M, Fisch MJ. Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer. J Cancer Surviv. 2014(Epub ahead of print).
  178. Loprinzi C. Chemotherapy-induced nausea and vomiting (cinv): Perceptions, mechanisms, and treatment guidelines. Journal of Managed Care Medicine. 2014; 17(2):45-9.
  179. Kadakia KC, Leal AD, Seisler DK, Qin R, Fee-Schroeder KC, Grendahl DC, Sorgatz KM, Loprinzi CL. Antiemetic prescribing practices using a computerized physician order entry system. Support Care Cancer. 2014 Jan; 22 (1):217-23 Epub 2013 Sept 13
    View PubMed
  180. Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, Petrelli NJ, Ryan K, Schrag DH, Wong SL, Benson AB 3rd, American Society of Clinical Oncology. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013 Dec 10; 31 (35):4465-70 Epub 2013 Nov 12
    View PubMed
  181. Lavoie Smith, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL. Assessing patient-reported peripheral neuropathy: the reliability and validity of the european organization for research and treatment of cancer qlq-cipn20 questionnaire. Qual Life Res. 2013 Dec; 22(10):2787-99.
    View PubMed
  182. Staff NP, Podratz JL, Grassner L, Bader M, Paz J, Knight AM, Loprinzi CL, Trushina E, Windebank AJ. Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology. 2013 Dec; 39:124-31. Epub 2013 Sep 12.
    View PubMed
  183. Pachman DR, Loprinzi CL, Novotny PJ, Satele DV, Linquist BM, Wolf S, Barton DL. Sternal skin conductance: a reasonable surrogate for hot flash measurement? Menopause. 2013 Nov; 20 (11):1164-8
    View PubMed
  184. Brown LC, Atherton PJ, Neben-Wittich MA, Wender DB, Behrens RJ, Kozelsky TF, Loprinzi CL, Haddock MG, Martenson JA. Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1. Support Care Cancer. 2013 Oct; 21 (10):2869-77 Epub 2013 June 08
    View PubMed
  185. Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR, McGinn TW, Stella PJ, Seeger GR, Sood A, Loprinzi CL. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013 Aug 21; 105 (16):1230-8 Epub 2013 July 13
    View PubMed
  186. Stan D, Loprinzi CL, Ruddy KJ. Breast cancer survivorship issues. Hematol Oncol Clin North Am. 2013 Aug; 27 (4):805-27, ix Epub 2013 June 19
    View PubMed
  187. Thompson CA, Hugo SE, Swetz KM, Novotny PJ, Sloan JA, Loprinzi CL, Moynihan TJ, Shanafelt TD. End-of-life care in a population-based cohort of cancer patients: clinical trial participation versus standard of care. BMJ Support Palliat Care. 2013 Jun; 3(2):181-7. Epub 2013 Mar 09.
    View PubMed
  188. Barton DL, Burger K, Novotny PJ, Fitch TR, Kohli S, Soori G, Wilwerding MB, Sloan JA, Kottschade LA, Rowland KM Jr, Dakhil SR, Nikcevich DA, Loprinzi CL. The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer. 2013 Apr; 21 (4):1185-92 Epub 2012 Nov 13
    View PubMed
  189. Roeland E, Loprinzi C, Moynihan TJ, Smith TJ, Temel J. In chemotherapy for lung cancer, sometimes less is more. J Natl Compr Canc Netw. 2013 Mar 1; 11(3):232-5.
    View PubMed
  190. Limburg PJ, Mandrekar SJ, Aubry MC, Ziegler KL, Zhang J, Yi JE, Henry M, Tazelaar HD, Lam S, McWilliams A, Midthun DE, Edell ES, Rickman OB, Mazzone P, Tockman M, Beamis JF, Lamb C, Simoff M, Loprinzi C, Szabo E, Jett J, Cancer Prevention Network. Randomized phase II trial of sulindac for lung cancer chemoprevention. Lung Cancer. 2013 Mar; 79 (3):254-61 Epub 2012 Dec 20
    View PubMed
  191. Sood R, Sood A, Wolf SL, Linquist BM, Liu H, Sloan JA, Satele DV, Loprinzi CL, Barton DL. Paced breathing compared with usual breathing for hot flashes. Menopause. 2013 Feb; 20(2):179-84.
    View PubMed
  192. Loprinzi C. Chemotherapy-induced nausea and vomiting (CINV): Perceptions, mechanisms, and treatment guidelines. Journal of Managed Care Medicine. 2013; 16(2):27-30.
  193. Ta LE, Schmelzer JD, Bieber AJ, Loprinzi CL, Sieck GC, Brederson JD, Low PA, Windebank AJ. A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PLoS One. 2013; 8 (1):e54161 Epub 2013 Jan 10
    View PubMed
  194. Peethambaram P, Olson J, Loprinzi CL. Soyfood consumption in breast cancer survivors: Don't overstate the facts! ONCOLOGY (United States). 2013; 27(5).
  195. Peterson DE, Ohrn K, Bowen J, Fliedner M, Lees J, Loprinzi C, Mori T, Osaguona A, Weikel DS, Elad S, Lalla RV, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer. 2013 Jan; 21(1):327-32. Epub 2012 Sep 21.
    View PubMed
  196. Pachman DR, Barton DL, Swetz KM, Loprinzi CL. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 2012 Oct 20; 30 (30):3687-96 Epub 2012 Sept 24
    View PubMed
  197. Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Kelaghan J, Novotny PJ, Lachance DH, Loprinzi CL. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012 Oct 15; 118 (20):5171-8 Epub 2012 Mar 13
    View PubMed
  198. Atherton PJ, Burger KN, Loprinzi CL, Neben Wittich MA, Miller RC, Jatoi A, Sloan JA. Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993). Support Care Cancer. 2012 Aug; 20(8):1729-35. Epub 2011 Sep 16.
    View PubMed
  199. Loprinzi PD, Cardinal BJ, Winters-Stone K, Smit E, Loprinzi CL. Physical activity and the risk of breast cancer recurrence: a literature review. Oncol Nurs Forum. 2012 May 1; 39(3):269-74.
    View PubMed
  200. Kadakia KC, Barton DL, Loprinzi CL, Sloan JA, Otley CC, Diekmann BB, Novotny PJ, Alberts SR, Limburg PJ, Pittelkow MR. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer. 2012 Apr 15; 118 (8):2128-37 Epub 2011 Aug 31
    View PubMed
  201. Kadakia KC, Moynihan TJ, Smith TJ, Loprinzi CL. Palliative communications: addressing chemotherapy in patients with advanced cancer. Ann Oncol. 2012 Apr; 23 Suppl 3:29-32.
    View PubMed
  202. Jones JM, Kohli M, Loprinzi CL. Androgen deprivation therapy-associated vasomotor symptoms. Asian J Androl. 2012 Mar; 14 (2):193-7 Epub 2012 Jan 30
    View PubMed
  203. Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, Aaronson NK, Satele DV, Mattar BI, Green NB, Loprinzi CL. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer. 2012 Mar; 20 (3):625-32 Epub 2011 Apr 12
    View PubMed
  204. Moraska AR, Moraska JM, Sideras K, Loprinzi CL. Management of hot flashes in breast cancer patients. European J Clin Med Oncol. 2012; 4(1):1-9.
  205. Jatoi A, Nieva JJ, Qin R, Loprinzi CL, Wos EJ, Novotny PJ, Moore DF Jr, Mowat RB, Bechar N, Pajon ER Jr, Hartmann LC. A pilot study of long-acting octreotide for symptomatic malignant ascites. Oncology. 2012; 82 (6):315-20 Epub 2012 May 10
    View PubMed
  206. Sandhu NP, Mac Bride MB, Dilaveri CA, Neal L, Farley DR, Loprinzi CL, Wahner-Roedler DL, Ghosh K. Male breast cancer. Journal of Men's Health. 2012; 9(3):146-53.
  207. Pruthi S, Qin R, Terstreip SA, Liu H, Loprinzi CL, Shah TR, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL. A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. Menopause. 2012 Jan; 19 (1):48-53
    View PubMed
  208. Pachman DR, Barton DL, Clayton AC, McGovern RM, Jefferies JA, Novotny PJ, Sloan JA, Loprinzi CL, Gostout BS. Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia. Am J Obstet Gynecol. 2012 Jan; 206 (1):42.e1-7 Epub 2011 July 13
    View PubMed
  209. Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, Smith DA, Berg AR, Stella PJ, Loprinzi CL. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer. 2011 Nov; 19 (11):1769-77 Epub 2010 Oct 09
    View PubMed
  210. Jatoi A, Dakhil SR, Sloan JA, Kugler JW, Rowland KM Jr, Schaefer PL, Novotny PJ, Wender DB, Gross HM, Loprinzi CL, North Central Cancer Treatment Group. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer. 2011 Oct; 19 (10):1601-7 Epub 2010 Sept 06
    View PubMed
  211. Neben-Wittich MA, Atherton PJ, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Loprinzi CL, Burger KN, Martenson JA, Miller RC. Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4). Int J Radiat Oncol Biol Phys. 2011 Oct 1; 81 (2):397-402 Epub 2010 Oct 01
    View PubMed
  212. Gill S, Loprinzi C, Kennecke H, Grothey A, Nelson G, Woods R, Speers C, Alberts SR, Bardia A, O'Connell MJ, Sargent DJ. Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. Cancer. 2011 Sep 15; 117(18):4155-65. Epub 2011 Mar 01.
    View PubMed
  213. Pachman DR, Barton DL, Watson JC, Loprinzi CL. Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther. 2011 Sep; 90 (3):377-87 Epub 2011 Aug 03
    View PubMed
  214. Pachman DR, Barton D, Carns PE, Novotny PJ, Wolf S, Linquist B, Kohli S, Smith DR, Loprinzi CL. Pilot evaluation of a stellate ganglion block for the treatment of hot flashes. Support Care Cancer. 2011 Jul; 19 (7):941-7 Epub 2010 May 23
    View PubMed
  215. Jones JM, Qin R, Bardia A, Linquist B, Wolf S, Loprinzi CL. Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Palliat Med. 2011 Jul; 14 (7):810-4 Epub 2011 May 09
    View PubMed
  216. Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD 3rd, Kugler JW, Hoff KL, Reddy PS, Rowland KM Jr, Riepl M, Christensen B, Loprinzi CL. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011 Jun; 19 (6):833-41 Epub 2010 May 25
    View PubMed
  217. Loprinzi CL, Balcueva EP, Liu H, Sloan JA, Kottschade LA, Stella PJ, Carlson MD, Moore DF Jr, Zon RT, Levitt R, Jaslowski AJ. A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment group study N04CA. J Support Oncol. 2011 May-Jun; 9 (3):105-12
    View PubMed
  218. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011 May; 12(5):489-95. Epub 2011 Feb 04.
    View PubMed
  219. Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Novotny PJ, Lachance DH. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011 Apr 10; 29 (11):1472-8 Epub 2011 Mar 07
    View PubMed
  220. Miller RC, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Stoffel TJ, Haselow RE, Schaefer PL, Bearden JD 3rd, Atherton PJ, Loprinzi CL, Martenson JA. Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. Int J Radiat Oncol Biol Phys. 2011 Apr 1; 79 (5):1460-6 Epub 2010 Aug 26
    View PubMed
  221. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Chitaley U, Alberts SR, Loprinzi CL. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2011 Feb 1; 29 (4):421-7 Epub 2010 Dec 28
    View PubMed
  222. Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Goetz MP. Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. Oncologist. 2011; 16(10):1359-66. Epub 2011 Sep 20.
    View PubMed
  223. Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, Stella PJ, Rowland KM Jr, Novotny PJ, Loprinzi CL. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol. 2011 Jan 01; 29: (1)97-105.
    View PubMed
  224. Barton DL, Atherton PJ, Bauer BA, Moore DF Jr, Mattar BI, Lavasseur BI, Rowland KM Jr, Zon RT, Lelindqwister NA, Nagargoje GG, Morgenthaler TI, Sloan JA, Loprinzi CL. The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5). J Support Oncol. 2011 Jan-Feb; 9 (1):24-31
    View PubMed
  225. Wolf SL, Qin R, Menon SP, Rowland KM Jr, Thomas S, Delaune R, Christian D, Pajon ER Jr, Satele DV, Berenberg JL, Loprinzi CL, North Central Cancer Treatment Group Study N05C5. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol. 2010 Dec 10; 28 (35):5182-7 Epub 2010 Nov 08
    View PubMed
  226. Bordeleau L, Pritchard KI, Loprinzi CL, Ennis M, Jugovic O, Warr D, Haq R, Goodwin PJ. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 2010 Dec 10; 28(35):5147-52. Epub 2010 Nov 08.
    View PubMed
  227. Sideras K, Loprinzi CL. Nonhormonal management of hot flashes for women on risk reduction therapy. J Natl Compr Canc Netw. 2010 Oct; 8 (10):1171-9
    View PubMed
  228. Loprinzi CL, Schapira L, Moynihan T, Kalemkerian GP, von Gunten, Steensma D. Compassionate honesty. J Palliat Med. 2010 Oct; 13(10):1187-91.
    View PubMed
  229. Moraska AR, Sood A, Dakhil SR, Sloan JA, Barton D, Atherton PJ, Suh JJ, Griffin PC, Johnson DB, Ali A, Silberstein PT, Duane SF, Loprinzi CL. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol. 2010 Aug 10; 28 (23):3673-9 Epub 2010 July 12
    View PubMed
  230. Pachman DR, Jones JM, Loprinzi CL. Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions. Int J Womens Health. 2010 Aug 9; 2:123-35 Epub 2010 Aug 09
    View PubMed
  231. Barton DL, LaVasseur BI, Sloan JA, Stawis AN, Flynn KA, Dyar M, Johnson DB, Atherton PJ, Diekmann B, Loprinzi CL. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol. 2010 Jul 10; 28 (20):3278-83 Epub 2010 May 24
    View PubMed
  232. Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, Goetz MP. Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol. 2010 Jun 1; 28 (16):2768-76 Epub 2010 May 03
    View PubMed
  233. Moraska AR, Atherton PJ, Szydlo DW, Barton DL, Stella PJ, Rowland KM Jr, Schaefer PL, Krook J, Bearden JD, Loprinzi CL. Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. J Support Oncol. 2010 May-Jun; 8 (3):128-32
    View PubMed
  234. Jatoi A, Ritter HL, Dueck A, Nguyen PL, Nikcevich DA, Luyun RF, Mattar BI, Loprinzi CL. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. 2010 May; 68 (2):234-9 Epub 2009 Aug 08
    View PubMed
  235. Hines SL, Sloan JA, Atherton PJ, Perez EA, Dakhil SR, Johnson DB, Reddy PS, Dalton RJ, Mattar BI, Loprinzi CL. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast. 2010 Apr; 19 (2):92-6 Epub 2010 Jan 15
    View PubMed
  236. Ta LE, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ. Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain. 2010 Mar 5; 6:15 Epub 2010 Mar 05
    View PubMed
  237. Kearns AE, Northfelt DW, Dueck AC, Atherton PJ, Dakhil SR, Rowland KM Jr, Fuloria J, Flynn PJ, Dentchev T, Loprinzi CL. Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8. Support Care Cancer. 2010 Mar; 18 (3):321-8 Epub 2009 May 27
    View PubMed
  238. Croghan IT, Hurt RD, Ebbert JO, Croghan GA, Polk OD, Stella PJ, Novotny PJ, Sloan J, Loprinzi CL. Racial differences in smoking abstinence rates in a multicenter, randomized, open-label trial in the United States. Z Gesundh Wiss. 2010 Feb; 18(1):59-68. Epub 2009 Aug 11.
    View PubMed
  239. Bardia A, Loprinzi C, Grothey A, Nelson G, Alberts S, Menon S, Thome S, Gill S, Sargent D. Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. Semin Oncol. 2010 Feb; 37(1):39-46.
    View PubMed
  240. Loprinzi CL, Qin R, Balcueva EP, Flynn KA, Rowland KM Jr, Graham DL, Erwin NK, Dakhil SR, Jurgens DJ, Burger KN. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol. 2010 Feb 1; 28 (4):641-7 Epub 2009 Nov 09
    View PubMed
  241. Barton DL, Soori GS, Bauer BA, Sloan JA, Johnson PA, Figueras C, Duane S, Mattar B, Liu H, Atherton PJ, Christensen B, Loprinzi CL. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer. 2010 Feb; 18 (2):179-87 Epub 2009 May 06
    View PubMed
  242. Bennett GJ, Grothey A, Loprinzi CL. Peripheral neurotoxicities. J Support Oncol. 2010; 8(2, suppl 1):22-3.
  243. Loprinzi CL. Vaginal estrogen therapy causes jump in serum estradiol level: Commentary. Oncol. Rep.. 2010; (Mar-Apr)44.
  244. Loprinzi CL. Stellate ganglion block may ease severe, refractory hot flashes: Commentary. Oncol. Rep.. 2010; (Mar-Apr)44.
  245. Loprinzi CL. Cancer and diarrhea: Rising incidence of an old problem - Commentary. Oncol. Rep.. 2010; (Mar-Apr)45.
  246. Loprinzi CL. Primary care providers uneasy on care for cancer survivorship: Commentary. Oncol. Rep.. 2010; (Mar-Apr)42.
  247. Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, Mattar BI, Nikcevich DA, Novotny P, Sekulic A, Loprinzi CL. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist. 2010; 15 (9):1016-22 Epub 2010 Aug 26
    View PubMed
  248. Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB, Schaefer PL, Alberts S, Liu H, Kahanic S, Mazurczak MA, Nikcevich DA, Loprinzi CL. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat. 2009 Oct; 117 (3):603-9 Epub 2009 Feb 12
    View PubMed
  249. Katipamula R, Degnim AC, Hoskin T, Boughey JC, Loprinzi C, Grant CS, Brandt KR, Pruthi S, Chute CG, Olson JE, Couch FJ, Ingle JN, Goetz MP. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol. 2009 Sep 1; 27 (25):4082-8 Epub 2009 July 27
    View PubMed
  250. Loprinzi CL, Diekmann B, Novotny PJ, Stearns V, Sloan JA. Newer antidepressants and gabapentin for hot flashes: a discussion of trial duration. Menopause. 2009 Sep-Oct; 16 (5):883-7
    View PubMed
  251. Loprinzi CL, Sloan J, Stearns V, Slack R, Iyengar M, Diekmann B, Kimmick G, Lovato J, Gordon P, Pandya K, Guttuso T Jr, Barton D, Novotny P. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol. 2009 Jun 10; 27 (17):2831-7 Epub 2009 Mar 30
    View PubMed
  252. Bardia A, Novotny P, Sloan J, Barton D, Loprinzi C. Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis. Menopause. 2009 May-Jun; 16 (3):477-83
    View PubMed
  253. Cheville AL, Sloan JA, Northfelt DW, Jillella AP, Wong GY, Bearden Iii JD, Liu H, Schaefer PL, Marchello BT, Christensen BJ, Loprinzi CL. Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB). Support Care Cancer. 2009 Apr; 17 (4):451-60 Epub 2009 Jan 13
    View PubMed
  254. Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner E, Loprinzi CL, Carlson MD, Atherton PJ, Salim M, Perez EA. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol. 2009 Mar 1; 27 (7):1047-53 Epub 2008 Dec 15
    View PubMed
  255. Dronca RS, Loprinzi CL, Hartmann LC. Breast cancer risk reduction: SERMs, surgery, and beyond Menopausal Management. 2009 Mar/Apr; 18(2):14-22.
  256. Loprinzi CL, Dueck AC, Khoyratty BS, Barton DL, Jafar S, Rowland KM Jr, Atherton PJ, Marsa GW, Knutson WH, Bearden JD 3rd, Kottschade L, Fitch TR. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol. 2009 Mar; 20 (3):542-9 Epub 2009 Jan 06
    View PubMed
  257. Zou H, Taylor WR, Harrington JJ, Hussain FT, Cao X, Loprinzi CL, Levine TR, Rex DK, Ahnen D, Knigge KL, Lance P, Jiang X, Smith DI, Ahlquist DA. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology. 2009 Feb; 136 (2):459-70 Epub 2008 Oct 15
    View PubMed
  258. Mincey B, Dentchev T, Sloan J, Hines S, Perez E, Johnson D, Schaefer P, Alberts S, Liu H, Wender D, Mazurczak M, Nikcevich D, Loprinzi C. Immediate vs. Delayed Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Starting Letrozole After Tamoxifen - N03CC. Breast Cancer Res Treat. 2009; 117:603-9.
  259. Loprinzi CL, Barton DL, Sloan JA, Novotny PJ, Wolf S. Newer antidepressants for hot flashes--should their efficacy still be up for debate? Menopause. 2009 Jan-Feb; 16(1):184-7.
    View PubMed
  260. Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, Beer TM. Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer. Cancer. 2008 Oct 15; 113(8):2205-14.
    View PubMed
  261. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, Lance MP, Burgart LJ, Hamilton SR, Allison JE, Lawson MJ, Devens ME, Harrington JJ, Hillman SL. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008 Oct 7; 149 (7):441-50, W81
    View PubMed
  262. Grothey A, Adjei AA, Alberts SR, Perez EA, Jaeckle KA, Loprinzi CL, Sargent DJ, Sloan JA, Buckner JC, North Central Cancer Treatment Group. North Central Cancer Treatment Group--achievements and perspectives. Semin Oncol. 2008 Oct; 35 (5):530-44
    View PubMed
  263. Loprinzi CL, Wolf SL, Barton DL, Laack NN. Symptom management in premenopausal patients with breast cancer. Lancet Oncol. 2008 Oct; 9 (10):993-1001
    View PubMed
  264. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008 Aug 15; 113 (4):847-53
    View PubMed
  265. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008 Jul; 44 (11):1507-15 Epub 2008 June 18
    View PubMed
  266. Loprinzi CL, Barton DL, Sloan JA, Novotny PJ, Dakhil SR, Verdirame JD, Knutson WH, Kelaghan J, Christensen B. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. Menopause. 2008 Jul-Aug; 15 (4 Pt 1):655-60
    View PubMed
  267. Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB, Gross HM, Renno SI, Nashawaty M, Loprinzi CL. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer. 2008 Jun 15; 112 (12):2802-8
    View PubMed
  268. Cheville A, Sloan J, Northfelt D, Jillella A, Wong G, Bearden J, Liu H, Schaefer P, Marchello B, Christensen B, Loprinzi C. The Efficacy of Lidocaine Patch in the Management of Postsurgical Neuropathic Pain in Patients with Cancer: A Phase III Double-Blind, Crossover Study (N01CB). J Pain Symp Manag. 2008.
  269. Bleicher J, Bhaskara A, Huyck T, Constantino S, Bardia A, Loprinzi CL, Silberstein PT. Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials. J Support Oncol. 2008 Jan; 6(1):27-32.
    View PubMed
  270. Thompson S, Bardia A, Tan A, Barton DL, Kottschade L, Sloan JA, Christensen B, Smith D, Loprinzi CL. Levetiracetam for the treatment of hot flashes: a phase II study. Support Care Cancer. 2008 Jan; 16(1):75-82. Epub 2007 Jun 28.
    View PubMed
  271. Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, Warner DO, Novotny P, Kutteh LA, Wong GY, North Central Cancer Treatment Group. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007 Nov 1; 110 (9):2110-8
    View PubMed
  272. Clark MM, Vickers KS, Hathaway JC, Smith M, Looker SA, Petersen LR, Pinto BM, Rummans TA, Loprinzi CL. Physical activity in patients with advanced-stage cancer actively receiving chemotherapy. J Support Oncol. 2007 Nov-Dec; 5(10):487-93.
    View PubMed
  273. Loprinzi CL, Maddocks-Christianson K, Wolf SL, Rao RD, Dyck PJ, Mantyh P, Dyck PJ, Dyck PJ. The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J. 2007 Nov-Dec; 13 (6):399-403
    View PubMed
  274. Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Rowland KM Jr, Soori GS, Wender DB, Fitch TR, Novotny PJ, Loprinzi CL. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer. 2007 Sep 15; 110 (6):1396-403
    View PubMed
  275. Barton DL, Loprinzi CL, Atherton P, Raymond J, Shanafelt T, Hines S, Palmieri F, Rummans T, Adjei AA, Sloan J. Phase II Evaluation of Desipramine for the Treatment of Hot Flashes. Support Cancer Ther. 2007 Sep 1; 4 (4):219-24
    View PubMed
  276. Kottschade L, Loprinzi C, Rao R. Vitamin e for the prevention of chemotherapy-induced peripheral neuropathy: rationale for an ongoing clinical trial. Support Cancer Ther. 2007 Sep 1; 4 (4):251-3
    View PubMed
  277. Pruthi S, Thompson SL, Novotny PJ, Barton DL, Kottschade LA, Tan AD, Sloan JA, Loprinzi CL. Pilot evaluation of flaxseed for the management of hot flashes. J Soc Integr Oncol. 2007 Summer; 5 (3):106-12
    View PubMed
  278. Barton DL, Wender DB, Sloan JA, Dalton RJ, Balcueva EP, Atherton PJ, Bernath AM Jr, DeKrey WL, Larson T, Bearden JD 3rd, Carpenter PC, Loprinzi CL. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. J Natl Cancer Inst. 2007 May 2; 99(9):672-9.
    View PubMed
  279. Perez DG, Zahasky KM, Loprinzi CL, Sloan J, Novotny P, Barton D, Pritchard KI. Tamoxifen-associated hot flashes in women. Support Cancer Ther. 2007 May 1; 4 (3):152-6
    View PubMed
  280. Halyard MY, Jatoi A, Sloan JA, Bearden JD 3rd, Vora SA, Atherton PJ, Perez EA, Soori G, Zalduendo AC, Zhu A, Stella PJ, Loprinzi CL. Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys. 2007 Apr 1; 67 (5):1318-22
    View PubMed
  281. Loprinzi CL, Barton DL, Jatoi A, Sloan J, Martenson J, Steensma D, Rao R, Novotny P, Sood A, Grothey A, Minasian L, Windschitl H. Symptom control trials: a 20-year experience. J Support Oncol. 2007 Mar; 5(3):119-25, 128.
    View PubMed
  282. Sood A, Barton DL, Bauer BA, Loprinzi CL. A critical review of complementary therapies for cancer-related fatigue. Integr Cancer Ther. 2007 Mar; 6(1):8-13.
    View PubMed
  283. Bordeleau L, Pritchard K, Goodwin P, Loprinzi C. Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review. Clin Ther. 2007 Feb; 29(2):230-41.
    View PubMed
  284. Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, Rowland KM, Bernath A, Loots ML, Le-Lindqwister NA, Tschetter LK, Garneau SC, Flynn KA, Ebbert LP, Wender DB, Loprinzi CL. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc. 2007 Feb; 82 (2):186-95
    View PubMed
  285. Loprinzi CL, Kugler JW, Barton DL, Dueck AC, Tschetter LK, Nelimark RA, Balcueva EP, Burger KN, Novotny PJ, Carlson MD, Duane SF, Corso SW, Johnson DB, Jaslowski AJ. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol. 2007 Jan 20; 25 (3):308-12 Epub 2006 Dec 04
    View PubMed
  286. Vincent A, Barton DL, Mandrekar JN, Cha SS, Zais T, Wahner-Roedler DL, Keppler MA, Kreitzer MJ, Loprinzi C. Acupuncture for hot flashes: a randomized, sham-controlled clinical study. Menopause. 2007 Jan-Feb; 14(1):45-52.
    View PubMed
  287. Barton DL, Loprinzi C, Jatoi A, Vincent A, Limburg P, Bauer B, Sood A, Good M, Bearden JD 4th, Kelaghan J, Sloan J. Can complementary and alternative medicine clinical cancer research be successfully accomplished? The Mayo Clinic-North Central Cancer Treatment Group experience. J Soc Integr Oncol. 2006 Fall; 4 (4):143-52
    View PubMed
  288. Markovic SN, Suman VJ, Ingle JN, Kaur JS, Pitot HC, Loprinzi CL, Rao RD, Creagan ET, Pittelkow MR, Allred JB, Nevala WK, Celis E. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol. 2006 Aug; 29 (4):352-60
    View PubMed
  289. Bardia A, Thompson S, Atherton PJ, Barton DL, Sloan JA, Kottschade LA, Christensen B, Collins M, Loprinzi CL. Pilot evaluation of aprepitant for the treatment of hot flashes. Support Cancer Ther. 2006 Jul 1; 3 (4):240-6
    View PubMed
  290. Alberts SR, Novotny PJ, Sloan JA, Danella J, Bostwick DG, Sebo TJ, Blute ML, Fitch TR, Levitt R, Lieberman R, Loprinzi CL. Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial. Am J Ther. 2006 Jul-Aug; 13 (4):291-7
    View PubMed
  291. Clark MM, Hurt RD, Croghan IT, Patten CA, Novotny P, Sloan JA, Dakhil SR, Croghan GA, Wos EJ, Rowland KM, Bernath A, Morton RF, Thomas SP, Tschetter LK, Garneau S, Stella PJ, Ebbert LP, Wender DB, Loprinzi CL. The prevalence of weight concerns in a smoking abstinence clinical trial. Addict Behav. 2006 Jul; 31 (7):1144-52 Epub 2005 Aug 30
    View PubMed
  292. Pockaj BA, Gallagher JG, Loprinzi CL, Stella PJ, Barton DL, Sloan JA, Lavasseur BI, Rao RM, Fitch TR, Rowland KM, Novotny PJ, Flynn PJ, Richelson E, Fauq AH. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol. 2006 Jun 20; 24 (18):2836-41
    View PubMed
  293. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton RF, Rowland KM, Novotny PJ, Loprinzi CL. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006 Jun; 81 (6):758-67
    View PubMed
  294. Perez DG, Loprinzi CL, Sloan J, Novotny P, Barton D, Carpenter L, Smith D, Christensen B, Rummans T. Pilot evaluation of bupropion for the treatment of hot flashes. J Palliat Med. 2006 Jun; 9(3):631-7.
    View PubMed
  295. Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD 3rd, Mailliard JA, Tschetter LK, Fitch TR, Kugler JW. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol. 2006 Mar 20; 24 (9):1409-14 Epub 2006 Feb 27
    View PubMed
  296. Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland KM Jr, Dentchev T, Novotny PJ, Tschetter LK, Alberts SR, Hogan TF, Law A, Loprinzi CL. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol. 2006 Mar 1; 24 (7):1079-89
    View PubMed
  297. Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC, National Comprehensive Cancer Network. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw. 2006 Mar; 4 Suppl 1:S1-26.
    View PubMed
  298. Barton DL, Loprinzi C, Atherton PJ, Kottschade L, Collins M, Carpenter P, Adjei A, Rummans TA, Shanafelt T, Christensen B, Sloan J. Dehydroepiandrosterone for the treatment of hot flashes: a pilot study. Support Cancer Ther. 2006 Jan 1; 3 (2):91-7
    View PubMed
  299. Loprinzi CL. Antidepressants and gabapentin. Menopause Management. 2006; 15(suppl 1):29-32.
  300. Sood A, Barton DL, Loprinzi CL. Use of methylphenidate in patients with cancer. Am J Hosp Palliat Care. 2006 Jan-Feb; 23: (1)35-40.
    View PubMed
  301. Loprinzi CL, Stearns V, Barton D. Centrally active nonhormonal hot flash therapies. Am J Med. 2005 Dec 19; 118 Suppl 12B:118-23
    View PubMed
  302. Perez EA, Suman VJ, Rowland KM, Ingle JN, Salim M, Loprinzi CL, Flynn PJ, Mailliard JA, Kardinal CG, Krook JE, Thrower AR, Visscher DW, Jenkins RB. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec; 6(5):425-32.
    View PubMed
  303. Desch CE, Benson AB, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Pfister DG, Virgo KS, Petrelli NJ. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol. 2005 Nov 20; 23(33):8512-19.
    View PubMed
  304. Loprinzi CL, Flynn PJ, Carpenter LA, Atherton P, Barton DL, Shanafelt TD, Rummans TA, Sloan JA, Adjei AA, Mincey BA, Fitch TR, Collins M. Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine. J Palliat Med. 2005 Oct; 8 (5):924-30
    View PubMed
  305. Perez DG, Loprinzi CL. Newer antidepressants and other nonhormonal agents for the treatment of hot flashes. Compr Ther. 2005 Fall; 31 (3):224-36
    View PubMed
  306. Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore DF Jr, Krook JE, Rowland KM Jr, Mazurczak MA, Berg AR, Kim GP, North Central Cancer Treatment Group. Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer. 2005 Jul 1; 104(1):176-82.
    View PubMed
  307. Vickers KS, Hathaway JC, Patten CA, Clark MM, Britt TL, Looker SA, Johnson PT, Loprinzi CL. Cancer patients' and patient advocates' perspectives on a novel information source: a qualitative study of the art of oncology, when the tumor is not the target. J Clin Oncol. 2005 Jun 20; 23(18):4013-20.
    View PubMed
  308. Ryan M, Moynihan TJ, Loprinzi CL. As-needed morphine: yes, but at what dose and at what interval? J Clin Oncol. 2005 Jun 1; 23(16):3849-52.
    View PubMed
  309. Adelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer. Expert Opin Pharmacother. 2005 Jun; 6(7):1095-106.
    View PubMed
  310. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2005 Apr 20; 23(12):2606-17. Epub 2004 Sep 27.
    View PubMed
  311. Loprinzi CL, Moynihan TJ. Mastering the art of oncology. Minn Med. 2005 Apr; 88(4):34-5, 54.
    View PubMed
  312. Whelan TJ, Loprinzi C. Physician/patient decision aids for adjuvant therapy. J Clin Oncol. 2005 Mar 10; 23(8):1627-30.
    View PubMed
  313. Hoda D, Jatoi A, Burnes J, Loprinzi C, Kelly D. Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A single institution's is 20-year experience. Cancer. 2005 Feb 15; 103(4):863-8.
    View PubMed
  314. Molina JR, Barton DL, Loprinzi CL. Chemotherapy-induced ovarian failure: manifestations and management. Drug Saf. 2005; 28 (5):401-16
    View PubMed
  315. Okuno S, Foote R, Olmscheid M, Sloan J, Sapiente R, Novotny P, Anthes M, Loprinzi C. An Evaluation of an Oral Capsaicin Lozenge for Preventing Radiation-Induced Mucoxtitis J of Cancer Integrative Medicine. 2005; 2:179-183.
  316. Loprinzi CL, Moynihan TJ. Discussing your chemotherapy treatment options with your doctor. Coping. 2005:20-3.
  317. Jatoi A, Jett JR, Sloan J, Novotny P, Ford J, Prabhakar U, Loprinzi CL. A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. Support Care Cancer. 2004 Dec; 12 (12):859-63 Epub 2004 Sept 15
    View PubMed
  318. Loprinzi CL, Barton DL, Carpenter LA, Sloan JA, Novotny PJ, Gettman MT, Christensen BJ. Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc. 2004 Oct; 79 (10):1247-51
    View PubMed
  319. Jatoi A, Egner J, Loprinzi CL, Sloan JA, Novotny PJ, Dakhil SR, Mailliard JA, Klee GG, Krook JE. Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial. Support Care Cancer. 2004 Sep; 12 (9):640-4
    View PubMed
  320. Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny PJ, Mailliard JA, Bushey TI, Nair S, Christensen B, North Central Cancer Treatment Group. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004 Jun 15; 22 (12):2469-76
    View PubMed
  321. Shanafelt TD, Loprinzi C, Marks R, Novotny P, Sloan J. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol. 2004 May 15; 22(10):1966-74.
    View PubMed
  322. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004 May 15; 22 (10):1797-806 Epub 2004 Apr 05
    View PubMed
  323. Barton D, Wilwerding M, Carpenter L, Carpenter L, Loprinzi C. Libido as part of sexuality in female cancer survivors. Oncol Nurs Forum. 2004 May; 31 (3):599-609
    View PubMed
  324. Barton D, Loprinzi CL. Making sense of the evidence regarding nonhormonal treatments for hot flashes. Clin J Oncol Nurs. 2004 Feb; 8 (1):39-42
    View PubMed
  325. Perez DG, Loprinzi CL, Barton DL, Pockaj BA, Sloan J, Novotny PJ, Christensen BJ. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol. 2004 Jan-Feb; 2 (1):50-6
    View PubMed
  326. Witzig T, Silberstein P, Loprinzi C, Sloan J, Novotny P, Mailliard J, Rowland K, Alberts S, Nikcevich D, Levitt R, Morton R. A Phase III Randomized Double-Blind Study of Epoetin alfa Versus Placebo in Anemic Patients with Cancer Undergoing Chemotherapy J Clin Oncol. 2004; 22:1-12.
  327. Okuno SH, Foote RL, Olmscheid MA, Sloan JA, Sapiente RA, Novotny PJ, Anthes ML, Loprinzi CL. Evaluation of an oral capsaicin lozenge for preventing radiation-induced mucositis. Journal of Cancer Integrative Medicine. 2004; 2(4):179-83.
  328. Pockaj BA, Loprinzi CL, Sloan JA, Novotny PJ, Barton DL, Hagenmaier A, Zhang H, Lambert GH, Reeser KA, Wisbey JA. Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Invest. 2004; 22 (4):515-21
    View PubMed
  329. Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH, Jatoi A, Moynihan TJ. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol. 2003 Nov-Dec; 1(4):274-8.
    View PubMed
  330. Hoda D, Perez DG, Loprinzi CL. Hot flashes in breast cancer survivors. Breast J. 2003 Sep-Oct; 9 (5):431-8
    View PubMed
  331. Jatoi A, Suman VJ, Schaefer P, Block M, Loprinzi C, Roche P, Garneau S, Morton R, Stella PJ, Alberts SR, Pittelkow M, Sloan J, Pagano R. A phase II study of topical ceramides for cutaneous breast cancer. Breast Cancer Res Treat. 2003 Jul; 80(1):99-104.
    View PubMed
  332. Loprinzi C, Rajkumar SV. Why not start with thalidomide? J Clin Oncol. 2003 Jun 1; 21(11):2211-4.
    View PubMed
  333. Barton DL, Loprinzi CL, Novotny P, Shanafelt T, Sloan J, Wahner-Roedler D, Rummans TA, Christensen B, Dakhill SR, Martin LS. Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol. 2003 May-Jun; 1 (1):47-51
    View PubMed
  334. Loprinzi CL, Hayes D, Smith T. Doc, shouldn't we be getting some tests? J Clin Oncol. 2003 May 1; 21(9 Suppl):108s-111s.
    View PubMed
  335. Loprinzi CL, Johnson ME, Steer G. Doc, how much time do I have? J Clin Oncol. 2003 May 1; 21(9 Suppl):5s-7s.
    View PubMed
  336. Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL, Mailliard JA, Ebbert LP, Swan DK, Walsh DJ, Wiesenfeld M, Levitt R, Stella P, Johnson PA, Tschetter LK, Loprinzi C. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob Res. 2003 Apr; 5 (2):181-7
    View PubMed
  337. Loprinzi CL, Ravdin PM. Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians. J Natl Compr Canc Netw. 2003 Apr; 1 (2):189-96
    View PubMed
  338. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003 Mar 6; 348(10):883-90.
    View PubMed
  339. Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ, Kardinal CG, Knost JA, Tirona MT, Addo F, Morton RF, Michalak JC, Schaefer PL, Porter PA, Stella PJ. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. J Clin Oncol. 2003 Mar 1; 21 (5):914-20
    View PubMed
  340. Stearns V, Loprinzi CL. New therapeutic approaches for hot flashes. Journal of Supportive Oncology. 2003; 1(1):11-21.
    View PubMed
  341. Thompson CA, Shanafelt TD, Loprinzi CL. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist. 2003; 8 (5):474-87
    View PubMed
  342. Sloan JA, Vargas-Chanes D, Kamath CC, Sargent DJ, Novotny P, Atherton P, Allmer C, Fridley BL, Frost M, Loprinzi CL. Detecting worms, ducks, and elephants: A simple approach for defining clinically relevant effects in quality-of-life measures. Journal of Cancer Integrative Medicine. 2003; 1(1):41-7.
  343. Barton DL, Loprinzi CL, Gostout B. Management of menopausal symptoms in cancer patients. Menopause Digest. 2003; 15(2):26-7.
  344. Jatoi A, Loprinzi CL. The cancer anorexia/weight loss syndrome-a review of therapeutic strategies. Business Briefing:European PharmacoTherapy. 2003;102-4.
  345. Witizig T, T S, Loprinzi C, Sloan J, Novotny P, Mailliard J, Rowland K, Levitt R, Morton R. A Phase III Randomized Double-Blind Study of Epoetin alfa Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy J of Clin Oncol. 2003.
  346. Barton D, Loprinzi C, Quella S, Sloan J, Pruthi S, Pruthi S, Novotny P. Depomedroxyprogesterone acetate for hot flashes. J Pain Symptom Manage. 2002 Dec; 24 (6):603-7
    View PubMed
  347. Barton D, Loprinzi C. Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible. Clin Breast Cancer. 2002 Dec; 3 Suppl 3:S121-7
    View PubMed
  348. Loprinzi L, Barton DL, Sloan JA, Zahasky KM, Smith DA, Pruthi S, Novotny PJ, Perez EA, Christensen BJ. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc. 2002 Nov; 77 (11):1159-63
    View PubMed
  349. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc. 2002 Nov; 77(11):1207-18.
    View PubMed
  350. Thome SD, Loprinzi CL, Heldebrant MP. Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas. Mayo Clin Proc. 2002 Sep; 77(9):913-7.
    View PubMed
  351. Hammack JE, Michalak JC, Loprinzi CL, Sloan JA, Novotny PJ, Soori GS, Tirona MT, Rowland KM Jr, Stella PJ, Johnson JA. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain. 2002 Jul; 98 (1-2):195-203
    View PubMed
  352. Loprinzi CL, Barton DL, Rhodes DJ, Wahner-Roedler DL. Newer antidepressants for hot flashes. Patient Care. 2002 Jul; 36(9):45-6, 49-51.
  353. Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, Novotny PJ, Poon MA, O'Connell MJ, Loprinzi CL. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002 Mar 15; 20 (6):1491-8
    View PubMed
  354. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novotny PJ, Rummans TA. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002 Mar 15; 20 (6):1578-83
    View PubMed
  355. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002 Jan 15; 20 (2):567-73
    View PubMed
  356. Jatoi A, Yamashita J, Sloan JA, Novotny PJ, Windschitl HE, Loprinzi CL. Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. Support Care Cancer. 2002 Jan; 10 (1):71-5
    View PubMed
  357. Barton DL, Loprinzi C, Gostout B. Current management of menopausal symptoms in cancer patients. Oncology (Williston Park). 2002 Jan; 16: (1)67-72, 74; discussion 75-6, 79-80.
    View PubMed
  358. Barton DL, Loprinzi CL, Ko MG. Managing hot flashes: The truth about the alternatives to traditional hormone replacement therapy. Menopause Manage. 2002;11(3):15-19.
  359. Barton D, La Vasseur B, Loprinzi C, Novotny P, Wilwerding MB, Sloan J. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum. 2002 Jan-Feb; 29 (1):33-40
    View PubMed
  360. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol. 2001 Dec 1; 19 (23):4280-90
    View PubMed
  361. Messina MJ, Loprinzi CL. Soy for breast cancer survivors: a critical review of the literature. J Nutr. 2001 Nov; 131(11 Suppl):3095S-108S.
    View PubMed
  362. Loprinzi CL, Barton DL, Rhodes DJ, Wahner-Roedler DL. Newer antidepressants for hot flashes. Contemp Ob Gyn. 2001 Nov; 46(11):61-2, 64, 67 passim.
  363. Jatoi A, Loprinzi CL, Sloan JA, Klee GG, Windschitl HE. Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigation. Cancer. 2001 Aug 1; 92 (3):629-33
    View PubMed
  364. Sloan JA, Loprinzi CL, Laurine JA, Novotny PJ, Vargas-Chanes D, Krook JE, O'Connell MJ, Kugler JW, Tirona MT, Kardinal CG, Wiesenfeld M, Tschetter LK, Hatfield AK, Schaefer PL. A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol. 2001 Aug 1; 19 (15):3539-46
    View PubMed
  365. Jatoi A, Loprinzi CL. An update: cancer-associated anorexia as a treatment target. Curr Opin Clin Nutr Metab Care. 2001 May; 4 (3):179-82
    View PubMed
  366. Jatoi A, Loprinzi CL. Current management of cancer-associated anorexia and weight loss. Oncology (Williston Park). 2001 Apr; 15: (4)497-502, 508; discussion 508-10.
    View PubMed
  367. Loprinzi CL, Barton DL, Rhodes D. Management of hot flashes in breast-cancer survivors. Lancet Oncol. 2001 Apr; 2(4):199-204.
    View PubMed
  368. Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol. 2001 Feb 15; 19 (4):972-9
    View PubMed
  369. Barton D, Loprinzi C, Wahner-Roedler D. Hot flashes: aetiology and management. Drugs Aging. 2001; 18 (8):597-606
    View PubMed
  370. Loprinzi CL, Goldberg RM, Su JQ, Mailliard JA, Kuross SA, Maksymiuk AW, Kugler JW, Jett JR, Ghosh S, Pfeifle DM, Wender DB, Burch OA. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small cell lung cancer. J Clin Oncol (Classic Papers and Current Comments). 2001; 92: (3)139-43.
  371. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000 Dec 16; 356(9247):2059-63.
    View PubMed
  372. Benson AB 3rd, Desch CE, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Petrelli NJ, Pfister DG, Smith TJ, Somerfield MR. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol. 2000 Oct 15; 18(20):3586-8.
    View PubMed
  373. Loprinzi CL, Hayes D, Smith T. Doc, shouldn't we be getting some tests? J Clin Oncol. 2000 Jun; 18: (11)2345-8.
    View PubMed
  374. Sloan JA, Novotny PJ, Loprinzi CL. Design and analysis of cancer control studies using the SAS system. SUGI 25 Proceedings. 2000 Apr 9-12:259-25.
  375. Loprinzi CL, Zahasky KM, Sloan JA, Novotny PJ, Quella SK. Tamoxifen-induced hot flashes. Clin Breast Cancer. 2000 Apr; 1 (1):52-6
    View PubMed
  376. Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, LaVasseur BI, Swan D, Krupp KR, Miller KD, Novotny PJ. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol. 2000 Mar; 18 (5):1068-74
    View PubMed
  377. Loprinzi CL, Alberts SR, Christensen BJ, Hanson LJ, Farley DR, Broers JK, Betcher DL, Grady RE, Southorn PA, Johnson TM, Perez EA. History of the development of antiemetic guidelines at Mayo Clinic Rochester. Mayo Clin Proc. 2000 Mar; 75 (3):303-9
    View PubMed
  378. Loprinzi CL, Johnson ME, Steer G. Doc, how much time do I have? J Clin Oncol. 2000 Feb; 18: (3)699-701.
    View PubMed
  379. Sloan JA, Loprinzi CL, Novotny PJ, Okuno S, Nair S, Barton DL. Sex differences in fluorouracil-induced stomatitis. J Clin Oncol. 2000 Jan; 18: (2)412-20.
    View PubMed
  380. Sloan J, Loprinzi C, Novotny P, Okuno S, Barton D, Nair S. Gender differences in 5FU-induced stomatitis J Clin Oncol. 2000; 18(2):412-420.
  381. Jatoi A, Loprinzi CL. Nutritional determinants of survival among patients with breast cancer. Surg Clin North Am. 1999 Oct; 79 (5):1145-56
    View PubMed
  382. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM Jr, Camoriano JK, Novotny PJ, Christensen BJ. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexiacachexia. J Clin Oncol. 1999 Oct; 17: (10)3299-306.
    View PubMed
  383. Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA, Burch PA, Antolak SJ Jr, Pisansky TM. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol. 1999 Jul; 162(1):98-102.
    View PubMed
  384. Bretscher M, Rummans T, Sloan J, Kaur J, Bartlett A, Borkenhagen L, Loprinzi C. Quality of life in hospice patients. A pilot study. Psychosomatics. 1999 Jul-Aug; 40 (4):309-13
    View PubMed
  385. Ingle JN, Suman VJ, Johnson PA, Krook JE, Mailliard JA, Wheeler RH, Loprinzi CL, Perez EA, Jordan VC, Dowsett M. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res. 1999 Jul; 5 (7):1642-9
    View PubMed
  386. Okuno SH, Woodhouse CO, Loprinzi CL, Sloan JA, LaVasseur BI, Clemens-Schutjer D, Swan D, Axvig C, Ebbert LP, Tirona MR, Michalak JC, Pierson N. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am J Clin Oncol. 1999 Jun; 22 (3):258-61
    View PubMed
  387. Desch CE, Benson AB 3rd, Smith TJ, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Petrelli NJ, Pfister DG, Somerfield MR. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol. 1999 Apr; 17(4):1312.
    View PubMed
  388. Ingle JN, Suman VJ, Kardinal CG, Krook JE, Mailliard JA, Veeder MH, Loprinzi CL, Dalton RJ, Hartmann LC, Conover CA, Pollak MN. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer. 1999 Mar 15; 85 (6):1284-92
    View PubMed
  389. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat. 1999 Mar; 54 (2):117-22
    View PubMed
  390. Loprinzi CL, Kugler JW, Sloan JA, Rooke TW, Quella SK, Novotny P, Mowat RB, Michalak JC, Stella PJ, Levitt R, Tschetter LK, Windschitl H. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. N Engl J Med. 1999 Feb 4; 340(5):346-50.
    View PubMed
  391. Loprinzi CL, Johnston PB, Sloan JA, Novotny P, Ellison N. Have medical oncologists recently modified surveillance testing patterns for melanoma and/or breast cancer survivors? Cancer Research, Therapy & Control. 1999; 9(3-4):205-14.
  392. Okuno SH, Kozelsky T, Loprinzi CL, Nair S. Alleviation of gastrointestinal mucosal toxicity related to chemotherapy and radiation therapy: the NCCTG experience. Cancer Research, Therapy & Control. 1999; 9(3-4):193-6.
  393. Goldberg RM, Loprinzi CL. Cancer anorexia/cachexia. Cancer Treat Res. 1999; 100:31-41
    View PubMed
  394. McGinnis WL, Loprinzi CL, Buskirk SJ, Sloan JA, Drummond RG, Frank AR, Shanahan TG, Kahanic SP, Moore RL, Schild SE, Humphrey SL. Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis. J Clin Oncol (Classic Papers and Current Comments). 1999; 4: (2)328-32.
  395. Finck G, Barton DL, Loprinzi CL, Quella SK, Sloan JA. Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manage. 1998 Nov; 16(5):327-33.
    View PubMed
  396. Sloan JA, Loprinzi CL, Kuross SA, Miser AW, O'Fallon JR, Mahoney MR, Heid IM, Bretscher ME, Vaught NL. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998 Nov; 16: (11)3662-73.
    View PubMed
  397. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Novotny PJ, Rummans TA, Dumesic DA, Perez EA. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 1998 Jul; 16 (7):2377-81
    View PubMed
  398. Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL, Fischer T, Finck G, Pierson N, Pisansky T. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer. 1998 May 1; 82(9):1784-8.
    View PubMed
  399. Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR, Fidler P, Stella PJ, Swan DK, Vaught NL, Novotny P. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 1998 Feb; 16: (2)495-500.
    View PubMed
  400. Sloan JA, Novotny PJ, Loprinzi CL. Analyzing quality of life data via the SAS system. SUGI. 1998; 23:1213-22.
  401. Pritchard K, Loprinzi CL. Estrogen/hormone replacement therapy (ERT/HRT) in women with a previous diagnosis of breast cancer: is it safe and are there alternatives? ASCO Fall Educational Book. 1998:81-6.
  402. Sloan JA, Novotny PJ, Loprinzi CL. Analyzing Quality of Life (QOL) Endpoints in Clinical Trials via the SAS System. Statistics Data Analysis, and Modeling. 1998:1213-1222.
  403. Perez EA, Loprinzi CL, Sloan JA, Owens DT, Novotny PJ, Bonner JA. Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma. Cancer. 1997 Aug 15; 80(4):676-80.
    View PubMed
  404. Ellison N, Loprinzi CL, Kugler J, Hatfield AK, Miser A, Sloan JA, Wender DB, Rowland KM, Molina R, Cascino TL, Vukov AM, Dhaliwal HS, Ghosh C. Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. J Clin Oncol. 1997 Aug; 15(8):2974-80.
    View PubMed
  405. Ingle JN, Johnson PA, Suman VJ, Gerstner JB, Mailliard JA, Camoriano JK, Gesme DH Jr, Loprinzi CL, Hatfield AK, Hartmann LC. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer. 1997 Jul 15; 80 (2):218-24
    View PubMed
  406. Peethambaram P, Weiss M, Loprinzi CL, Novotny P, O'Fallon JR, Erlichman C, O'Connell MJ, Laurie JA. An evaluation of postoperative follow-up tests in colon cancer patients treated for cure. Oncology. 1997 Jul-Aug; 54(4):287-92.
    View PubMed
  407. Okuno SH, Foote RL, Loprinzi CL, Gulavita S, Sloan JA, Earle J, Earle J, Novotny PJ, Burk M, Frank AR. A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer. 1997 Jun 1; 79 (11):2193-9
    View PubMed
  408. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland KM Jr, Law M, Windschitl HE, Kaur JS, Ellison N. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol. 1997 Mar; 15 (3):969-73
    View PubMed
  409. Loprinzi CL, Ghosh C, Camoriano J, Sloan J, Steen PD, Michalak JC, Schaefer PL, Novotny PJ, Gerstner JB, White DF, Hatfield AK, Quella SK. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. J Clin Oncol. 1997 Mar; 15: (3)1235-8.
    View PubMed
  410. McGinnis WL, Loprinzi CL, Buskirk SJ, Sloan JA, Drummond RG, Frank AR, Shanahan TG, Kahanic SP, Moore RL, Schild SE, Humphrey SL. Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis. J Clin Oncol. 1997 Mar; 15(3):1239-43.
    View PubMed
  411. Chong SF, Bretscher ME, Mailliard JA, Tschetter LK, Kimmel DW, Hatfield AK, Loprinzi CL. Pilot study evaluating local anesthetics administered systemically for treatment of pain in patients with advanced cancer. J Pain Symptom Manage. 1997 Feb; 13(2):112-7.
    View PubMed
  412. Loprinzi CL, Goldberg RM, Su JQ, Mailliard JA, Kuross SA, Maksymiuk AW, Kugler JW, Jett JR, Ghosh C, Pfeifle DM, Wender DB, Burch PA. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small cell lung cancer. J Clin Oncol (Classic Papers and Current Comments). 1997; 2: (1)253-7.
  413. Sloan J, Novotny P, Loprinzi C, Nair S. Graphical and analytical tools for the analysis of two-period crossover clinical trials SAS Users Group International (SUGI) Conference Proceedings. 1997; 22:1312-1317.
  414. Hammack JE, Mailliard JA, Loprinzi CL, Rospond RM, O'Fallon JR, Wilwerding MB, Reuter NF, Michalak JC, Fidler P, Miser AW. Transdermal fentanyl in the management of cancer pain in ambulatory patients: an open-label pilot study. J Pain Symptom Manage. 1996 Oct; 12 (4):234-40
    View PubMed
  415. Williams MS, Burk M, Loprinzi CL, Hill M, Schomberg PJ, Nearhood K, O'Fallon JR, Laurie JA, Shanahan TG, Moore RL, Urias RE, Kuske RR, Engel RE, Eggleston WD. Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity. Int J Radiat Oncol Biol Phys. 1996 Sep 1; 36(2):345-9.
    View PubMed
  416. Pisansky TM, Loprinzi CL, Cha SS, Fitzgibbons RJ Jr, Grant CS, Hass AC, Reuter NF, Wold LE, Ingle JN, Kardinal CG. A pilot evaluation of alternating preoperative chemotherapy in the management of patients with locoregionally advanced breast carcinoma. Cancer. 1996 Jun 15; 77(12):2520-8.
    View PubMed
  417. Loprinzi CL, Okuno Sh, Okuno Sh, Pisansky TM, Sterioff S, Gaffey TA, Morton RF. Postsurgical changes of the breast that mimic inflammatory breast carcinoma. Mayo Clin Proc. 1996 Jun; 71 (6):552-5
    View PubMed
  418. Loprinzi CL, Messing EM, O'Fallon JR, Poon MA, Love RR, Quella SK, Trump DL, Morton RF, Novotny P. Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. Cancer Epidemiol Biomarkers Prev. 1996 May; 5(5):371-4.
    View PubMed
  419. Loprinzi CL, Athmann LM, Kardinal CG, O'Fallon JR, See JA, Bruce BK, Dose AM, Miser AW, Kern PS, Tschetter LK, Rayson S. Randomized trial of dietician counseling to try to prevent weight gain associated with breast cancer adjuvant chemotherapy. Oncology. 1996 May-Jun; 53 (3):228-32
    View PubMed
  420. Fidler P, Loprinzi CL, O'Fallon JR, Leitch JM, Lee JK, Hayes DL, Novotny P, Clemens-Schutjer D, Bartel J, Michalak JC. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer. 1996 Feb 1; 77(3):522-5.
    View PubMed
  421. Rowland KM Jr, Loprinzi CL, Shaw EG, Maksymiuk AW, Kuross SA, Jung SH, Kugler JW, Tschetter LK, Ghosh C, Schaefer PL, Owen D, Washburn JH Jr, Webb TA, Mailliard JA, Jett JR. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetateplacebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol. 1996 Jan; 14: (1)135-41.
    View PubMed
  422. Loprinzi CL. Management of menopausal symptoms in breast cancer survivors. ASCO Spring Educational Book. 1996.
  423. Loprinzi CL. North Central Cancer Treatment Group (NCCTG). J Natl Cancer Inst Monogr. 1996; 20:79-80.
    View PubMed
  424. Loprinzi CL, Smith TJ. Surveillance testing in curatively-treated cancer survivors. ASCO Educational Book. 1996:29-32.
  425. Loprinzi , Charles L.. Quality of life in clinical cancer trials. NCCTG experience. J Natl Cancer Inst Monogr. 1996; 20:79-80.
  426. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995 Dec 06; 274: (21)1703-5.
    View PubMed
  427. Loprinzi CL, Peethambaram PP. Management of menopausal symptoms in breast cancer patients. Ann Med. 1995 Dec; 27 (6):653-6
    View PubMed
  428. Goldberg RM, Loprinzi CL, Mailliard JA, O'Fallon JR, Krook JE, Ghosh C, Hestorff RD, Chong SF, Reuter NF, Shanahan TG. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol. 1995 Nov; 13 (11):2856-9
    View PubMed
  429. Loprinzi CL, Foote RL, Michalak J. Alleviation of cytotoxic therapy-induced normal tissue damage. Semin Oncol. 1995 Apr; 22(2 Suppl 3):95-7.
    View PubMed
  430. Wilwerding MB, Loprinzi CL, Mailliard JA, O'Fallon JR, Miser AW, Vanhaelst C, Barton DL, Foley JF, Athmann LM. A randomized crossover evaluation of methyphenidate in cancer patients receiving strong narcotics. Support Care Cancer. 1995 Mar; 3:135-8.
    View PubMed
  431. Loprinzi CL. Management of cancer anorexia/cachexia. Support Care Cancer. 1995 Mar; 3 (2):120-2
    View PubMed
  432. Loprinzi CL. How to manage cancer anorexia/cachexia. Contemporary Oncology Cancer, and HIV-Associated Anorexia and , Evaluation, and Management (Suppl)11-3. 1995 Mar; Cachexia:Mechanisms.
  433. Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C, Klatt NE, Bate WW, Rospond RM, Oesterling JE. Megestrol acetate for the prevention of hot flashes. Obstet Gynecol Surv. 1995 Feb; 50(2):135-137.
  434. Au E, Loprinzi CL, Dhodapkar M, Nelson T, Novotny P, Hammack J, O'Fallon J. Regular use of a verbal pain scale improves the understanding of oncology inpatient pain intensity. J Clin Oncol. 1994 Dec; 12: (12)2751-5.
    View PubMed
  435. Foote RL, Loprinzi CL, Frank AR, O'Fallon JR, Gulavita S, Tewfik HH, Ryan MA, Earle JM, Novotny P. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol. 1994 Dec; 12: (12)2630-3.
    View PubMed
  436. Quella S, Loprinzi CL, Dose AM. A qualitative approach to defining "hot flashes" in men. Urol Nurs. 1994 Dec; 14 (4):155-8
    View PubMed
  437. Ingle JN, Kuross SA, Mailliard JA, Loprinzi CL, Jung SH, Nelimark RA, Krook JE, Long HJ. Evaluation of piroxantrone in women with metastatic breast cancer and failure on nonanthracycline chemotherapy. Cancer. 1994 Sep 15; 74 (6):1733-8
    View PubMed
  438. Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C, Klatt NE, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994 Aug 11; 331(6):347-52.
    View PubMed
  439. Loprinzi CL, Wender DB, Veeder MH, O'Fallon JR, Vaught NL, Dose AM, Ghosh C, Bartel J, Leitch JM. Inhibition of 5-fluorouracil-induced ocular irritation by ocular ice packs. Cancer. 1994 Aug 1; 74 (3):945-8
    View PubMed
  440. Loprinzi CL, Ravdin PM, de Laurentiis M, Novotny P. Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer? J Clin Oncol. 1994 Jul; 12: (7)1422-6.
    View PubMed
  441. Loprinzi CL, Kuross SA, O'Fallon JR, Gesme DH Jr, Gerstner JB, Rospond RM, Cobau CD, Goldberg RM. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol. 1994 Jun; 12: (6)1121-5.
    View PubMed
  442. Loprinzi CL, Goldberg RM, Su JQ, Mailliard JA, Kuross SA, Maksymiuk AW, Kugler JW, Jett JR, Ghosh C, Pfeifle DM. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol. 1994 Jun; 12: (6)1126-9.
    View PubMed
  443. Miser AW, Goh TS, Dose AM, O'Fallon JR, Niedringhaus RD, Betcher DL, Simmons P, MacKellar DJ, Arnold M, Loprinzi CL. Trial of a topically administered local anesthetic (EMLA cream) for pain relief during central venous port accesses in children with cancer. J Pain Symptom Manage. 1994 May; 9 (4):259-64
    View PubMed
  444. Hammack JE, Loprinzi CL. Use of orally administered opioids for cancer-related pain. Mayo Clin Proc. 1994 Apr; 69 (4):384-90
    View PubMed
  445. Loprinzi CL, Goldberg RM, O'Fallon JR, Quella SK, Miser AW, Mynderse LA, Brown LD, Tschetter LK, Wilwerding MB, Dose M. Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J Urol. 1994 Mar; 151 (3):634-6
    View PubMed
  446. Loprinzi CL, Laurie JA, Wieand HS, Krook JE, Novotny PJ, Kugler JW, Bartel J, Law M, Bateman M, Klatt NE. Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol. 1994 Mar; 12: (3)601-7.
    View PubMed
  447. Goldberg RM, Loprinzi CL, O'Fallon JR, Veeder MH, Miser AW, Mailliard JA, Michalak JC, Dose AM, Rowland KM, Burnham NL. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 1994 Jan; 12(1):155-8.
    View PubMed
  448. Loprinzi CL. Phase III cancer chemoprevention trials: how do they contrast with cancer treatment trials? ASCO Educational Book. 1994; 29-33.
  449. Hammack J, Loprinzi C. Use of orally administered opioids for cancer-related pain Mayo Clinic Proc. 1994; 69:384-390.
  450. Loprinzi C. Phase III cancer chemoprevention trials: How do they contrast with cancer treatment trials? Proc Am Soc Clin Oncol. 1994:29-33.
  451. Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G, Lifsey D, Glaw KC, Stevens BA, Hatfield AK. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer. 1993 Oct 1; 72(7):2234-8.
    View PubMed
  452. Creagan ET, Schaid DJ, Hartmann LC, Loprinzi CL. A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma. Am J Clin Oncol. 1993 Jun; 16 (3):243-4
    View PubMed
  453. Loprinzi CL, Michalak JC, Schaid DJ, Mailliard JA, Athmann LM, Goldberg RM, Tschetter LK, Hatfield AK, Morton RF. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol. 1993 Apr; 11 (4):762-7
    View PubMed
  454. Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr; 11: (4)768-70.
    View PubMed
  455. Ahlquist DA, Wieand HS, Moertel CG, McGill DB, Loprinzi CL, O'Connell MJ, Mailliard JA, Gerstner JB, Pandya K, Ellefson RD. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA. 1993 Mar 10; 269: (10)1262-7.
    View PubMed
  456. Loprinzi CL, O'Fallon JR. Symptom control research in a cooperative oncology group. Advances in Medical Psychotherapy. 1993; 6:241-246.
  457. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol. 1993 Jan; 11: (1)152-4.
    View PubMed
  458. Loprinzi CL. Pharmacologic management of cancer anorexia/cachexia. Oncology. 1993; 7:101-103.
  459. Davis T, Miser AW, Loprinzi CL, Kaur JS, Burnham NL, Dose AM, Ames MM. Comparative morphine pharmacokinetics following sublingual, intramuscular, and oral administration in patients with cancer. Hosp J. 1993; 9(1):85-90.
    View PubMed
  460. Loprinzi CL, Jensen MD, Jiang NS, Schaid DJ. Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clin Proc. 1992 Dec; 67 (12):1160-2
    View PubMed
  461. Pisansky TM, Schaid DJ, Loprinzi CL, Donohue JH, Schray MF, Schomberg PJ. Inflammatory breast cancer: integration of irradiation, surgery, and chemotherapy. Am J Clin Oncol. 1992 Oct; 15(5):376-87.
    View PubMed
  462. Loprinzi CL, Goldberg RM, Burnham NL. Cancer-associated anorexia and cachexia. Implications for drug therapy. Drugs. 1992 Apr; 43 (4):499-506
    View PubMed
  463. Loprinzi CL, Goldberg RM, Burnham NL. Cancer-Associated Anorexia and Cachexia : Implications for Drug Therapy. Drugs. 1992 Apr; 43 (4):499-506
    View PubMed
  464. Loprinzi CL, Johnson PA, Jensen M. Megestrol acetate for anorexia and cachexia. Oncology. 1992; 49 Suppl 2:46-9
    View PubMed
  465. Loprinzi CL, Goldberg RM, Burnham N. Cancer - associated anorexia and cachexia: implications for drug therapy. New Ethicals. 1992; 29:125-131.
  466. Loprinzi CL, Messing EM. A prospective clinical trial of difluoromethylornithine (DFMO) in patients with resected superficial bladder cancer. J Cell Biochem Suppl. 1992; 16I:153-5
    View PubMed
  467. Witzig TE, Loprinzi CL, Gonchoroff NJ, Reiman HM, Cha SS, Wieand HS, Katzmann JA, Paulsen JK, Moertel CG. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer. 1991 Aug 15; 68 (4):879-88
    View PubMed
  468. Ingle ,, Long ,, Loprinzi ,, Mailliard ,, Schaid ,, Krook ,, Dalton ,, Gesme ,, Windschitl ,, Pfeifle ,, Etzell ,, Gerstner ,, Foley ,. A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic Cancer. 1991; 68(1):34-39.
    View PubMed
  469. Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Therneau TM, Sorensen JM, Gainey DK, Mailliard JA, Gusa NL, Goldberg R. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol. 1991 Mar; 9(3):449-52.
    View PubMed
  470. Loprinzi CL, Ingle JN, Schaid DJ, Buckner JC, Edmonson JH, Allegra CJ. 5-Fluorouracil plus leucovorin in women with metastatic breast cancer. A phase II study. Am J Clin Oncol. 1991 Feb; 14 (1):30-2
    View PubMed
  471. Ransom DT, Neuberg D, Loprinzi CL, Tormey DC, Blum RH, Harris JE, Asbury RF, Falkson G. A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer. Am J Clin Oncol. 1991 Feb; 14 (1):45-8
    View PubMed
  472. Loprinzi CL, Ellison NM, Goldberg RM, Michalak JC, Burch PA. Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group. Semin Oncol. 1990 Dec; 17 (6 Suppl 9):8-12
    View PubMed
  473. Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol. 1990 Aug; 8 (8):1327-34
    View PubMed
  474. Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM, Mailliard JA, Johnson PS, Ebbert LP, Geeraerts LH. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst. 1990 Jul 4; 82(13):1127-32.
    View PubMed
  475. Ames MM, Loprinzi CL, Collins JM, van Haelst-Pisani C, Richardson RL, Rubin J, Moertel CG. Phase I and clinical pharmacological evaluation of pirozantrone hydrochloride (oxantrazole). Cancer Res. 1990 Jul 1; 50(13):3905-9.
    View PubMed
  476. Kardinal CG, Loprinzi CL, Schaid DJ, Hass AC, Dose AM, Athmann LM, Mailliard JA, McCormack GW, Gerstner JB, Schray MF. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer. 1990 Jun 15; 65(12):2657-62.
    View PubMed
  477. Loprinzi CL, Cianflone SG, Dose AM, Etzell PS, Burnham NL, Therneau TM, Hagen L, Gainey DK, Cross M, Athmann LM. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. Cancer. 1990 Apr 15; 65 (8):1879-82
    View PubMed
  478. Krook JE, Loprinzi CL, Schaid DJ, Kardinal CG, Mailliard JA, Pfeifle DM, Ellison NM, Reuter NF, Nelimark RA. Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer. A collaborative North Central Cancer Treatment Group/Mayo Clinic phase II study. Cancer. 1990 Feb 1; 65(3):418-21.
    View PubMed
  479. Loprinzi CL, Love RR, Garrity JA, Ames MM. Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity. Cancer Invest. 1990; 8 (5):459-65
    View PubMed
  480. Loprinzi CL, Dose AM. Studies on the prevention of 5-fluorouracil-induced oral mucositis. NCI Monogr. 1990; (9):93-4.
    View PubMed
  481. Coltman CA, Abrams JS, Aisner J, Cruz JM, Hellerstein MK, Loprinzi CL, Paterson AHG, Schacter LP, Von Roenn JH. Therapy to promote weight gain in cancer and acquired immunodeficiency syndrome patients: a panel discussion (part I). Semin Oncol. 1990; 17:34-37.
  482. Gallenberg MM, Loprinzi CL. Breast cancer and pregnancy. Semin Oncol. 1989 Oct; 16 (5):369-76
    View PubMed
  483. Edmonson JH, Buckner JC, Long HJ, Loprinzi CL, Schaid DJ. Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas. J Natl Cancer Inst. 1989 Jun 7; 81 (11):863-6
    View PubMed
  484. Loprinzi CL, Rasmussen PW, Tormey DC, Carbone PP. Combined modality treatment of local regionally advanced breast cancer patients. 5 to 10 year follow-up. Am J Clin Oncol. 1989 Jun; 12 (3):208-12
    View PubMed
  485. Loprinzi CL. 5-Fluorouracil with leucovorin in breast cancer. Cancer. 1989 Mar 15; 63 (6 Suppl):1045-7
    View PubMed
  486. Loprinzi CL, Love RR, Therneau TM, Verman AK. Inhibition of human skin ornithine decarboxylase activity by oral alpha-diflouromethylornithine. Cancer Therapy and Control. 1989; 1:75-80.
  487. Loprinzi CL, Burnham NL, O'Connell MJ, Svingen PA, Peterson DA. Allopurinol mouthwash kinetic and stability information based on normal volunteers. Hosp Pharm. 1989; 24:353-354.
  488. Loprinzi C, Miser A, Kardinal C, Everson L, Ahlquist D, Dose A, Moertel C. Advances in Cancer Control: Innovations & Research Cancer control research in the North Central Cancer Treatment Group.. 1989; 345-53.
  489. Loprinzi CL, Miser AW, Kardinal C, Everson LK, Ahlquist DA, Dose AM, Moertel CG. Cancer control research in the North Central Cancer Treatment Group (NCCTG). Prog Clin Biol Res. 1989; 293:345-53.
    View PubMed
  490. Creagan ET, Loprinzi CL, Ahmann DL, Schaid DJ. A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-gamma in patients with metastatic malignant melanoma. Cancer. 1988 Dec 15; 62 (12):2472-4
    View PubMed
  491. Long HJ, Schaid DJ, Schutt AJ, Ingle JN, Loprinzi CL, Edmonson JH. Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy. Am J Clin Oncol. 1988 Oct; 11 (5):524-7
    View PubMed
  492. Loprinzi CL, Ingle JN, Schaid DJ, Buckner JC, Edmonson JH. Progress report on a phase II trial of 5-fluorouracil plus citrovorum factor in women with metastatic breast cancer. Adv Exp Med Biol. 1988; 244:255-9
    View PubMed
  493. Richardson RL, Schutt AJ, O'Connell MJ, Creagan ET, Loprinzi CL, Powis G. Phase I study of amonafide (a) (nsc-308847) given by 24-hour continuous intravenous infusion (24h-civ) every 4 weeks. Proc Annu Meet Am Soc Clin Oncol. 1987 Mar; 6:35.
  494. Loprinzi CL, Tormey DC, Rasmussen P, Falkson G, Davis TE, Falkson HC, Chang AY. Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. J Clin Oncol. 1986 Jan; 4(1):46-56.
    View PubMed
  495. Loprinzi CL, Verma AK. Dose and schedule of oral retinoic acid and indomethacin needed to effectively inhibit phorbol ester-induced epidermal ornithine decarboxylase activity. Carcinogenesis. 1985 Nov; 6(11):1589-92.
    View PubMed
  496. Verma AK, Loprinzi CL, Boutwell RK, Carbone PP. In vitro induction of human skin ornithine decarboxylase by the tumor prompter 12-0-tetradecanoylphorbol-13-acetate. J Natl Cancer Inst. 1985 Jul; 75:85-90.
    View PubMed
  497. Loprinzi CL, Verma AK, Boutwell RK, Carbone PP. Inhibition of phorbol ester-induced human epidermal ornithine decarboxylase activity by oral compounds: a possible role in human chemoprevention studies. J Clin Oncol. 1985; 3:751-756.
    View PubMed
  498. Loprinzi CL, Verma AK. Studies on the dose and schedule of alpha-difluoromethylornithine needed to inhibit ornithine decarboxylase activity in mice. Cancer Lett. 1985; 28:327-333.
    View PubMed
  499. Loprinzi CL, Verma AK. Effects of local anesthetics on phorbol ester-induced ornithine decarboxylase activity in mouse and human skin. Anticancer Res. 1984 Nov-Dec; 4(6):363-6.
    View PubMed
  500. Trump DL, Loprinzi CL. Phase II trial of etoposide in advanced prostate cancer. Cancer Treat Rep. 1984 Sep; 68(9):1195-6.
    View PubMed
  501. Davis TE, Loprinzi CL, Buchler DA. Combination chemotherapy with cisplatin, vinblastine, and bleomycin for endodermal sinus tumor of the ovary. Gynecol Oncol. 1984 Sep; 19(1):46-52.
    View PubMed
  502. Loprinzi CL, Carbone PP, Tormey DC, Rosenbaum PR, Caldwell W, Kline JC, Steeves RA, Ramirez G. Aggressive combined modality therapy for advanced local-regional breast carcinoma. J Clin Oncol. 1984 Mar; 2(3):157-63.
    View PubMed
  503. Loprinzi CL. Mitomycin C induced pulmonary and renal toxicity. Wis Med J. 1984; 83:16-17.
    View PubMed
  504. Jaffe JP, Loprinzi CL. Basophilic-eosinophilic meningitis in an undifferentiated myeloproliferative disorder. JAMA. 1983 Jan 7; 249(1):73-4.
    View PubMed
  505. Loprinzi CL, Heaton JW Jr, Kelly PC. Enterohepatic fistulas associated with amebic liver abscesses. South Med J. 1983; 76:384-386.
    View PubMed
  506. Loprinzi CL, Hennessee J, Tamsky L, Johnson TE. Snake antivenom administration in a patient allergic to horse serum. South Med J. 1983; 76:501-502.
    View PubMed
  507. Loprinzi CL. Prostatic cancer. South Med J. 1982 Feb; 75(2):193-6.
    View PubMed
PST-20219801